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Summary
Fenbendazole is a thio-substituted benzimidazole used in the treatment of 
helminths of domestic animals. It has poor water solubility and is rapidly 
biotransformed and eliminated from the animals’ body. These features are 
common to the ‘newer’ benzimidazoles and pose a serious constraint on 
their efficacy, especially in the equine species with short gut transit time. 
Anthelmintic activity of the benzimidazoles is related to the period of time 
the parasite is exposed to effective concentrations of the active 
compounds (i.e. the parent sulphide and the sulphoxide metabolite), 
consequently residence time of the active compound is important.
The effect of administering fenbendazole with food , and/or in combination 
with the metabolic inhibitor, piperonyl butoxide, was investigated. Six adult 
horses were administered 10 mg/kg fenbendazole with or without food, 
and with or without piperonyl butoxide, 63 mg/kg, in a series of 
experiments.
Feeding was shown to affect the disposition kinetics of fenbendazole and 
it’s metabolites. The mean residence time of fenbendazole was only very 
slightly reduced but that of the sulphoxide was reduced by 67%, and the 
inactive metabolite (sulphone) was prolonged in the blood when the 
parent compound was administered with food. Feeding was also found to 
delay the time to reach Cmax ,and reduce (by 50.4%) the total area under 
the plasma concentration-time curve of the active metabolites (AUCSU|phide 
+ AUCSU|ph0Xide). In respect of these findings, feeding reduces the relative 
bioavailability of the active metabolites and horses would be better 
administered fenbendazole on an empty stomach.
The methylenedioxyphenyl (MDP) compound, piperonyl butoxide, was 
used in the metabolism studies in the horse. When fenbendazole was co­
administered with piperonyl butoxide the relative bioavailability of the 
active metabolites was enhanced. This was attributed to the piperonyl 
butoxide-mediated metabolic inhibition of the cytochrome P450 enzyme-
catalyzed sulphoxidation and sulphonation reactions resulting in increased 
amounts of the active compounds. In comparison to the unfed animals not 
receiving piperonyl butoxide, the piperonyl butoxide-treated unfed animals 
showed increases in the AUC, AUMC and Cmax values of 10, 8 and 7 
times, respectively, for the sulphide, fenbendazole, whereas the same 
parameters for the sulphoxide were reduced. In the piperonyl butoxide- 
treated fed horses, these parameters were even higher, compared to the 
same parameters in the unfed animals not receiving piperonyl butoxide, 
and this applied to the sulphoxide values as well. The mean residence 
times were increased in all cases except for the sulphoxide metabolite in 
the unfed horses. Piperonyl butoxide markedly improved the effectiveness 
of fenbendazole whether administered with food or without. In vitro 
metabolism studies using equine liver microsomes were also conducted. 
Piperonyl butoxide reduced the extent of metabolism of fenbendazole in 
vitro by 38.4% when a fenbendazole: piperonyl butoxide ratio of 1: 5 was 
used. The rate of sulphoxidation was drastically reduced (by 90%) with the 
co-administration of the inhibitor but there was little effect on the rate of 
sulphonation, and the sulphonation: sulphoxidation ratio was increased. 
The results of the in vitro studies supported the in vivo findings.
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Chapter 1 
Review of literature
21.1 Introduction
The discovery and development of novel chemicals for use against 
helminth parasites is becoming increasingly more difficult. The cost of 
research and drug development is very high due to strict regulations on 
potential toxicity. Lengthy mandatory trials are required to determine likely 
teratogenic or mutagenic effects and diverse studies on non-target 
invertebrate and vertebrate species must be undertaken. It has been 
estimated that the discovery, research and development of a novel 
pharmaceutical product intended for use in food-producing animals may 
cost $US 100-200 million and takes about 12 years (Hennessy, 1997). For 
drugs meant for use in food animals, the additional costs of extensive 
studies to determine when residues are at acceptable levels have to be 
considered. For anthelmintic drugs nematode resistance constitutes 
another major problem. Reports of anthelmintic resistance are increasing 
worldwide. Helminths have become resistant to various anthelmintics, 
including the recent endectocides, such as ivermectin and moxidectin and 
to the salicylanilide, closantel. The problem seems inevitable and the life 
expectancy of any new anthelmintic compound is limited and 
unpredictable.
The problems and costs associated with the discovery and development 
of new anthelmintic drugs have prompted investigations into alternative 
methods of treatment and management of helminthiosis. These include 
means of achieving more effective use of currently available anthelmintics 
and non-chemical control strategies, such as grazing management and 
biological, immunological and genetic methods.
31.2 Anthelmintics in horses.
Equine anthelmintic drugs can be allocated chemically into seven distinct 
classes (Table 1.1) with each class affecting a different range of parasites 
and having a different pharmacological behaviour.
Desirable attributes of an ideal equine anthelmintic include: high efficacy, 
broad spectrum of activity, low host toxicity and high safety index, easy to 
administer, environmentally safe, relatively inexpensive and unlikely to 
select for drug resistance (Herd, 1992). An anthelmintic with all these 
attributes has yet to be found.
The broad spectrum anthelmintic drugs are commonly classified into three 
classes: Benzimidazoles and pro-benzimidazoles; Imidazothiazoles and 
tetrahydropyrimidines; and avermectins and milbemycins. Specific 
examples of representative drugs are shown in Table 1.1. The other drugs 
have a narrow spectrum of activity except for some of the 
organophosphates.
1.2.1 Mode of action
Anthelmintics used in horses affect parasites either by altering metabolic 
processes necessary for survival of the parasites or by causing a 
disturbance in muscular activity that results in paralysis (DiPietro and 
Todd, 1989).
The benzimidazoles and probenzimidazoles affect energy production by 
inhibiting fumarate reductase and glucose uptake, and binding to tubulin. 
Binding of tubulin blocks polymerization into microtubules thereby 
damaging the integrity and transport functions of the absorptive cells 
within the parasite. Drugs causing a disturbance in neuromuscular activity 
do so by inhibiting the breakdown of excitatory neurotransmitters,
4Table 1.1 Chemical classification of anthelmintics used in the horse and 
related compounds__________________________________________________
Class Route of 
administration
Representative drugs
Simple heterocyclics Phenothiazine, Piperazine
Probenzimidazoles* Febantel, Thiophanate
Benzimidazoles
(Thiazoles) P.O. Thiabendazole (TBZ)
(Carbamates) P.O. (I.R.) Albendazole (ABZ)* 
Fenbendazole (FBZ) 
Mebendazole (MBZ) 
Oxfendazole (OXF) 
Oxibendazole (OXI) 
Tioxidazole*
Macrocyclic lactones
Avermectins P.O., i.m./s.c., T Ivermectin, Abamectin* 
Doramectin*
Milbemycins Moxidectin, Milbemycin D 
Milbemycin oxime*
Imidazothiazole P.O.,s.c.,T Levamisole*
Tetrahydropyrimidines P.O. Pyrantel, Morantel*
Organophosphates P.O. Dichlorvos, Haloxon, 
Trichlorphon
*Not licenced for horses
5mimicking the inhibitory neurotransmitter or by mimicking the action of the 
excitatory neurotransmitter (Rew, 1978) or by stimulating glutamate gated 
chloride ion channels (McKellar and Benchaoui, 1996). The 
acetylcholinesterase inhibitors include organophosphates (e.g. dichlorvos, 
haloxon, trichlorphon). Cholinergic agonists (ganglionic) include 
quaternary ammonium salts (biphenium) imidazoles (levamisole), 
pyridines (methyrdine) and pyrimidines (pyrantel). Muscle hypopolarisers 
include piperazines (piperazine). GABA agonists include the macrocyclic 
lactones (e.g. ivermectin ) which are now thought to exert their 
nematocidal activity by stimulating glutamate gated chloride ion channels.
1.2.2 Anthelmintic resistance
The development of drug resistance is a major drawback in 
chemotherapeutics worldwide. Anthelmintic drug resistance is the 
heritable ability of some nematode parasites to survive treatment with 
anthelmintic drugs at the recommended therapeutic dose levels (Taylor 
and Hunt, 1989). Side resistance is resistance to different compounds 
within a class of anthelmintics and multiple resistance is resistance to 
more than one class of anthelmintic (Prichard et al.t 1980). Reversion is a 
return to susceptibility to an anthelmintic drug by an originally resistant 
parasite strain (Prichard etal., 1980).
The first report of anthelmintic drug resistance in horses was in North 
America in 1965 (Drudge and Lyons, 1965) in which strains of equine 
strongyles became resistant to thiabendazole barely four years after its 
discovery. Anthelmintic resistance is now recognised throughout the world 
in small strongyles to various classes of anthelmintics including 
benzimidazoles (McKellar and Scott, 1990) and pyrantel (Conder and
6Campbell, 1995). The majority of reports on anthelmintic resistance 
involve small strongyles (cyathostomes). Resistance to large strongyles 
has not been clearly demonstrated.
Development of anthelmintic resistance
As Geerts, Coles and Gryseels (1997) state, the key issue in the 
development of resistance is the contribution that helminths surviving 
therapy make to the next generation. These survivors are the most 
resistant component of the population and carry resistance genes which 
they pass to their offspring (Sangster, 1996). Over several generations the 
number of survivors of therapy increase as the number of genes 
conferring resistance accumulate (Sangster, 1996). A number of factors 
contribute to the selection of resistance including frequent dosing, 
underdosing, mass therapy and prolonged use of the same class of 
anthelmintic.
Selection for resistance appears to occur in three phases (Prichard, 
1990a). An initial anthelmintic susceptibility phase occurs whereby there 
are few drug resistant parasites in the population. This is followed by the 
development of a phase in which heterozygous resistant individuals 
predominate and finally, with continued selection pressure, a resistant 
phase develops which is predominated by homozygous resistant 
individuals.
Control strategies that involve the slow rotation of anthelmintics rely upon 
the possibility of reversion to susceptibility occurring in the intervening 
years between treatments with a single drug (Jackson, 1993). This 
reversion is most likely to occur during the heterozygous-resistant phase 
of development (Scott et a/., 1991). Unfortunately, a number of field 
studies on reversion provided little or no evidence of reversion in the
7absence of chemotherapy (Uhlinger and Johnstone, 1984; Martin, 1987; 
Borgsteede and Duyn, 1989).
Detection of anthelmintic resistance
Sound methods of detecting anthelmintic resistance in the field are yet to 
be developed. The existing assays for identifying anthelmintic resistance 
early in the developmental process are not efficient for field use. 
Comprehensive reviews on a variety of assays to monitor resistance have 
been published (Presidente, 1985; Johansen, 1989; Taylor and Hunt, 
1989; Coles, 1990).These assays can be grouped into in vitro and in vivo 
techniques (Taylor and Hunt, 1989).
The in vivo techniques are suitable for all chemical groups of 
anthelmintics. The in vivo techniques include the faecal egg count 
reduction test (FECRT) and the controlled efficacy test (CET). Though it 
has its own limitations, FECRT is probably the best technique for use in 
the field; it is the simplest and does not require highly skilled labour to 
carry out. However, it has poor sensitivity and is only capable of detecting 
high levels of resistance (Conder and Campbell, 1995). The controlled 
efficacy test is the definitive test for resistance but is very costly in terms of 
animals and labour (Johansen, 1989).
Most of the in vitro tests are best applied for research in the laboratory, 
they are rapid, sensitive and economical to use. The in vitro assays 
include those based on anthelmintic effects on normal physiological 
processes such as development, growth, and/or movement of parasitic 
stages include egg hatch, larval development, larval paralysis, motility and 
larval migration assays (Conder and Campbell, 1995). Biochemical based 
assays include the colorimetric assay of acetylcholinesterases (Sutherland 
et al., 1988; 1989) tubulin binding and polymerization assays (Lacey, 
1985; Lacey and Prichard, 1986; Lacey and Snowdon, 1988). Genetic
assays are available with benzimidazoles where resistant populations 
have been identified using cloned (3-tubulin probes (Roos et a/., 1990). Of 
the in vitro assays mentioned, only the egg hatch and the larval 
development assays are suitable for field survey investigations.
Control of Resistance
Since the relative flow of genes through generations is crucial for the 
development of drug resistance, several steps can be taken to delay and 
even avoid the problem. (Savioli et al., 1997). Evaluation of anthelmintic 
efficacy is an important procedure in the detection of drug resistance 
development in helminths. At least 20% of horses should be tested for the 
presence of nematode ova 7 to 14 days after drug therapy (Ewert et al., 
1991). Each and every horse sharing a grazing area should be subjected 
to the same anthelmintic protocol and new horses should be treated 
before being released onto the pasture. A new horse with drug-resistant 
worms can introduce those worms to the rest of the horses. Frequent 
treatment intervals predispose to the fast development of drug resistance 
and therefore these should be minimized to reduce the selection pressure 
for resistant parasites. The optimum treatment interval will vary according 
to the following: the number, age and population densities of the target 
horses; pasture management factors (e.g. manure-handling methods and 
micro-environment considerations); current level of parasitic infectivity in 
horses and in the grazing environment; and climatic and seasonal 
variations that determine the survival of the free-living stages (Uhlinger, 
1991).
Another control strategy to delay anthelmintic resistance is the use of a 
single class of anthelmintics annually to prevent multiple resistance and to 
rotate classes annually to limit passage of resistant genes (Conder and 
Campbell, 1995). The concept of rotation relies on the possibility that 
parasites revert to susceptibility after prolonged withdrawal of one class of
9drug, and subsequent reintroduction following administration of a different 
class (Jackson, 1993). However, a number of field studies conducted 
have provided little evidence of reversion in the absence of chemotherapy 
(Jackson, 1993).
Small strongyles that have developed resistance to benzimidazoles may 
be treated by: using piperazine, or the non-benzimidazole drugs 
ivermectin, dichlorvos or pyrantel pamoate. The benzimidazole, 
oxibendazole, has been shown to be effective against small strongyles 
that have developed resistance to other benzimidazoles (thiabendazole, 
mebendazole, cambendazole, fenbendazole and oxfendazole), but even 
this drug shows reduced efficacy after repeated treatments. The co­
administration of oxfendazole and parbendazole in sheep resulted in 
potentiation of the former by the latter by increasing systemic availability of 
the oxfendazole and thus efficacy (Hennessy et al., 1985).
Animals need to be administered an effective dose of a highly efficacious 
drug so that heterozygous resistant parasites (with genes which confer 
partial resistance) are effectively removed along with the susceptible 
individuals (Conder and Campbell, 1995).
Mathematical models are being developed for investigating the 
effectiveness of different control strategies but these are faced with 
various constraints such as limited understanding of the genetics of 
resistance and insufficient data on the epidemiology of helminthiosis.
1.2.3 Control of endoparasites
Horses, ponies, donkeys and other equidae are hosts to a variety internal 
parasites. Equine parasites in decreasing order of importance are: large 
strongyles, small strongyles, ascarids, bots, pinworms, and other parasites
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of minor importance including strongyloides, stomach worms, tapeworms, 
eye worms, and filaroids (Herd, 1992).
It is unfeasible, if not impossible, to eradicate parasitism. Control of 
helminthiosis is aimed at reducing the worm burden to levels that do not 
impair health, production and performance. The importance of parasitic 
disease varies widely with geographic area and management systems. 
Anthelmintic chemotherapy and chemoprophylaxis are vital in the fight 
against internal parasites. However, there is need to combine 
chemotherapy with other control strategies, namely effective 
managemental practices. This approach, referred to as integrated control, 
makes optimal use of available methods of control in a flexible way, 
adapted to local circumstances and to economic reality. Control 
intervention must be carried out at strategic periods in the parasitic life 
cycle. Epidemiological information is of vital importance in the design of 
effective control strategies to prevent the seasonal build-up of pasture 
contamination and infectivity. Effective management practices may include 
grazing management, use of optimal stocking rates, appropriate housing 
or confinement, good sanitation and adequate nutrition.
Considerable research is being carried out on alternative means of 
control, such as immunological, biological, ecological and genetic 
methods.
Immunological control
There are very few vaccines used against parasites. For the helminth 
parasites, only one vaccine is used commercially and this is the one for 
the lungworm of cattle Dictyocaulus viviparus (Jarett et al., 1959). A 
similar vaccine was developed in India in 1971 (Dhar and Sharma, 1981) 
for use against the lungworm, Dictyocaulus filaria, of sheep. A commercial 
vaccine against the canine hookworm Ancylostoma caninum was
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produced (Jarett et al., 1959; Miller 1971, 1978) but was short lived on the 
animal market due to certain constraints such as short shelf-life, high cost 
of production and failure to completely remove Ancylostoma caninum 
eggs and faeces even though the dogs did not develop pathological 
hookworm disease. It was withdrawn in 1975.
Current strategies for vaccine development are grouped into two broad 
categories, namely exploitation of excretory/secretory (E/S) antigens and 
‘hidden antigens’ (Newton, 1995). Excretory/secretory antigens or 
products are substances such as enzymes and metabolites that are 
released from the oral and genital openings, excretory pores and 
secretory glands of nematodes. ‘Hidden ‘ or concealed antigens are 
antigens located in the parasite gut. Antibody responses to these hidden 
antigens are lethal to the parasite when it invades and feeds on host fluids 
that contain induced antibodies to its internal tissues, such as gut cells 
(Soulsby, 1994).
The market for equine vaccines is generally small compared to that for the 
food and other companion animals. The cost of developing, testing and 
licensing a vaccine are the same regardless of the size of the market 
(Powell, 1992) and the pharmaceutical industry is hesitant to invest in the 
development of new equine vaccines, but would rather use technologies 
developed for vaccines in other species and adapt them to similar 
products in the horse (Powell, 1992). At present no practical vaccines 
against helminth parasites of the horse have been made. A horse harbors 
a mixed infection of parasites and it will be a Herculean task to produce a 
multivalent vaccine that will be effective against all the 10 major species of 
cyathostomes, for instance. Conventional vaccines are normally based on 
whole dead organisms or attenuated live preparations. With the recent 
advances in recombinant DNA technology, novel vaccines are being 
produced that are based on surface and extracellular components of
12
parasites, called protective antigens. Recombinant DNA technology has 
overcome the previously, apparently unsolvable, problem of how to 
produce sufficient antigen to make a practical vaccine for helminths. It 
involves the identification of the effective immunizing epitope (or antigenic 
protein required for the immune response); the isolation (or synthesis) of 
the gene coding for it; incorporation of the gene into a vector e.g. a 
plasmid; transfer of the vector into an appropriate recipient (host) e.g. 
Escherichia coli or yeast; selection and cloning of the host cells carrying 
the gene; expression of the gene; extraction of the protein; and scaling up 
production.
Genetic control
The immune response to endoparasites varies between different breeds, 
different populations and different individuals. Individuals harboring few 
helminths are genetically ‘high’ responders and those with heavy burdens 
are ‘low’ responders (Soulsby, 1994). Selective breeding for genetically 
immune hosts to endoparasites will in the long run convert a population to 
a high responder category and this will be a means of reducing the 
reliance upon chemotherapy (Rothwell et al., 1991). However, selection 
for breeding in horses is dependent on other phenotypic characteristics 
such as performance, appearance and temperament and it may be 
impossible to combine appropriate conventional characteristics with those 
of parasitic resistance.
Biological control
Biological control involves the use of predators of parasites to control 
parasitism. Fungi seem to be the most promising of the potential biological 
control agents (fungi, bacteria, viruses and protozoa).
In ruminants, a number a successful experiments have been performed in 
attempts to control the free-living larvae of trichostrongyles by means of
13
nematode-trapping fungi (Gr<|)nv<|)ld et a/., 1993a, b, c; Waller and Larsen, 
1996, Waller et al., 1994; Wolstrup et al, 1994, 1996; Larsen et a/., 1992; 
1995; Nansen et a/., 1995). Recent studies performed by Larsen et a/., 
(1995a, b; 1996) in horses have also demonstrated the potential of the 
fungus Duddingtonia flagrans for controlling free-living stages of horse 
parasitic nematodes.
1.2.4 Environmental impact of anthelmintic usage
This is an area that is increasingly receiving more attention, particularly 
from regulatory authorities. Residues or metabolites of phenothiazine, 
dichlorvos, coumaphos, ruelene and piperazine excreted in bovine faeces 
had deleterious effects on dung beetle in Texas (Blume et al., 1976). 
Phenothiazine is known to have harmful effects via excreted metabolites 
on pasture growth, clover content, nitrification rates and animal production 
(Southcott, 1980).
Decomposing animal faeces are beneficial to the ecosystem in that they 
return valuable nutrients to the soil. The dung fauna- fungi, yeast, 
bacteria, nematodes, insects and earthworms- play an important role in 
the decomposition process (Spratt, 1997). Insects, including dung beetles, 
also help aerate the pat, improve the humus content, enhance water 
percolation and recycle soil nutrients. The effect of ivermectin on the 
pasture ecosystem has been receiving special attention due to its potent 
insecticidal activity. Furthermore, it is mainly excreted in faeces mostly 
unchanged and in bile regardless of the species or route of administration 
(reviewed by McKellar and Benchaoui, 1996). Ivermectin has adverse 
effects on many dung degrading beetles and on dipteran flies.
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1.3 Benzimidazoles in horses
The first benzimidazole to be introduced was thiabendazole (TBZ) in 1961 
(Brown et al., 1961).Since then a number of benzimidazoles with improved 
efficacy and spectra of activity have been developed. They include 
mebendazole (MBZ), cambendazole (CBZ), fenbendazole (FBZ), 
oxfendazole (OXF), oxibendazole (OXI), and luxabendazole (LBZ).
Features common to the benzimidazole drugs are broad-spectrum of 
anthelmintic activity, low mammalian toxicity and relatively low dosage 
requirements.
1.3.1 Spectra of activity
All the benzimidazoles (and also the pro- benzimidazoles) used in equines 
are effective against Parascaris equorum, Oxyuris equi, adult
cyathostomes and adult large strongyles (see Table 1.2). Thiabendazole 
needs to be given at a higher dosage for P. equorum. Thiabendazole, 
oxibendazole and fenbendazole are effective against Strongloides westerii 
when given at a higher dose. Fenbendazole (at a high dosage) and 
oxfendazole are effective against migrating cyathostome larvae and large 
strongyles’ larvae. Fenbendazole is effective against Dictyocaulus amfieldi 
and oxfendazole is effective against Trichostrongylus axei. Nevertheless, 
both drugs are likely be effective against both nematodes but this has not 
yet been tested (McKellar, personal communications). Mebendazole is 
effective against both of these parasites. The benzimidazoles are not 
effective against bots.
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1.3.2 Safety, Toxicity and Teratogenicity.
The benzimidazole and pro-benzimidazole anthelmintics have high 
therapeutic indices. Their low water solubility could account for this low 
toxicity. The safety index (ratio of maximum tolerated dose to the 
recommended dose) ranges from 10 to 100 (Herd, 1992). The main toxic 
effect of benzimidazoles is their teratogenic effect which varies with 
benzimidazole structure and with target-animal species (Delatour and 
Parish, 1986). Sheep are the most sensitive of the domestic animals to 
the teratogenic effects of the benzimidazoles. Differences in the kinetics 
and drug metabolism in various species may account for the differences in 
the sensitivity to the teratogenic effects of the benzimidazoles (Delatour 
and Parish, 1986).
1.3.3 Mode of Action
Benzimidazoles exert their primary action by binding to the cytoskeletal 
protein, tubulin, and inhibiting the formation of the microtubule matrix 
which is essential to the normal functioning of all eukaryotic cells (Lacey 
and Gill, 1994). These anthelmintics are, however, more toxic to helminth 
cells than mammalian cells. This selective toxicity may be due to 
differences in the structure of the microtubules in the cells (Reviewed by 
McKellar and Scott, 1990). Mammalian cells have 13 protofilaments in 
microtubules whereas nematode cells have protofilaments varying 
between 11 and 15 (Chalfie and Thompson, 1979; Davis and Gull, 1983). 
One study revealed that there are differences in the affinities of 
benzimidazoles for host and parasite tubulin (Friedman and Platzer, 1980) 
and assumed that these differences could account for the benzimidazoles’ 
selective toxicity. However, a subsequent study failed to support this 
assumption. The differential pharmacokinetics of the benzimidazoles may 
also account for the selective toxicity (Kohler and Bachmann, 1981).
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1.3.4 Formulation and administration
The benzimidazoles are available in a variety of formulations including 
powders, pellets, suspensions, pastes and boluses. Most anthelmintics 
are formulated as oral dosage forms. The formulation of the drug dosage 
form largely determines the route of administration, which may in turn 
influence the clinical efficacy of the drug. Physicochemical properties that 
affect absorption (e.g. lipid solubility and degree of ionization) of the drug, 
stability of the drug in the gastrointestinal tract and drug release from the 
dosage form may influence absorption of drugs from oral formulations. 
The relatively poor water solubility of the benzimidazole anthelmintics 
precludes their use parenterally.
1.3.5 Pharmacokinetics of benzimidazoles
Pharmacokinetics is the study of the time course of drug and metabolite 
concentrations in animals and how these are affected by absorption, 
distribution, biotransformation and elimination processes. A knowledge of 
pharmacokinetics is essential in pharmaceutical drug research and 
development and in the optimal clinical use of drug formulations. 
Bioavailability (sometimes referred to as systemic availability) is defined 
as the rate and extent to which a drug enters the systemic circulation 
unchanged following administration by any route (Baggot, 1992). The 
route of administration of the dosage form affects the rate and the extent 
of absorption of a drug and may thereby influence the intensity and 
duration of the pharmacological effect. Maximum bioavailability is attained 
when a drug is directly administered into the vascular system or when it is 
administered by an extravascular route and is completely absorbed from 
that site of administration into the blood stream.
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The active benzimidazoles are thought to have a similar mode of action 
(Coles, 1977) and to be relatively equipotent. The different efficacies of 
the benzimidazoles in vivo have been attributed to different 
pharmacokinetics in the host (Bogan, 1983), and in vitro to different 
solubilities and consequent absorption by the parasite from culture 
medium (Scott, 1988), respectively. The benzimidazole anthelmintics are 
only sparingly soluble in water (Table 1.3). The newer benzimidazoles e.g. 
albendazole, oxfendazole and fenbendazole have more limited water 
solubility. Small differences on the solubilities of the anthelmintic drugs 
may have a significant influence in the absorption and hence on their 
resultant clinical efficacy. Thiabendazole and cambendazole are the most 
water soluble of the benzimidazoles. They are extensively dissolved in 
aqueous ruminal fluid and rapidly absorbed in ruminants (McKellar and 
Scott, 1990), having time to maximum concentration (tmax) values of as 
little as 4h in cattle (Tocco et al., 1965; Prichard, 1986). The less soluble 
benzimidazole drugs remain in the plasma for long periods, and since an 
equilibrium presumably exists between plasma and the gastrointestinal 
tract, the duration of exposure of the parasites to effective concentrations 
of drugs is extended.
The absorption of drugs administered orally may be affected by drug 
release from the dosage form, the stability of the drug in the 
gastrointestinal tract and the physicochemical properties that govern 
absorption ( e.g. degree of ionization and lipid solubility) of the drug. The 
absorption of a drug following oral administration involves the transfer of 
the drug from within the gastrointestinal tract into the plasma of the portal 
vein, from which it reaches the systemic circulation via the liver. Drugs
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Table 1.3. The solubility (jag/ml) of benzimidazoles in phosphate buffer at 
different pH values (Ngumuo, 1983)
pH 7.4 pH 6.0 pH 2.2
Thiabendazole 45.01 >24.67 >480.78
Albendazole 0.85 >0.48 >26.58
Fenbendazole 0.05 >0.07 >1.60
Oxfendazole 5.97 >3.01 >44.12
Parbendazole 0.20 >0.27 >27.07
passing through the liver undergo some degree of hepatic metabolism 
called the ‘first pass effect’. The first pass effect in horses is quite 
significant owing to the high rate of activity of the hepatic microsomal 
enzymes in this species. Generally, for the benzimidazoles, absorption is 
rapid with Cmax values occurring within 2-7 hours after administration for 
TBZ, FLBZ, or MBZ and 6 to 30 hours for ABZ, FBZ, OXF, OXI, PBZ or 
TPT. Marked species differences in the kinetics of the benzimidazoles 
exist. The benzimidazoles have lower bioavailability in monogastric 
animals (horses and dogs ) than in the ruminant species. This is attributed 
to the rapid gut transit times in monogastrics. In one study carried out, the 
horse was found to have a gut transit time of 8.47 hours (Dougherty,
1992). In ruminants, the gut transit time may range from 30 to 80 hours 
depending on the digestibility of the food, since highly digestible food has 
shorter retention time (McDonald et al., 1995; Warner, 1981). In a study 
done in horses, oxfendazole and fenbendazole were shown to have area 
under the plasma concentration curve (AUC) values of 3.17 and 2.32
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pg.h/ml respectively after administration of 10mg/kg of oxfendazole 
(Marriner and Bogan, 1985). After administration of fenbendazole at the 
same dose rate, lower plasma concentrations of oxfendazole and 
fenbendazole were obtained, with oxfendazole being below the limit of 
detection (<0.04ng/ml) and fenbendazole with an AUC of 1.77 pg.h/ml 
(Marriner and Bogan, 1985). In contrast to other species (sheep, cattle, 
man), the horse has high sulphone metabolite relative to the sulphoxide 
and this may be due to the relatively rapid rate of conversion of the 
sulphoxide to the sulphone (Marriner and Bogan, 1985). Anthelmintic 
activity is related to the duration of parasite exposure to effective 
concentrations of the active compound (Baggot and McKellar, 1994), and 
consequently the pharmacokinetics of FBZ and OXF in horses make 
these drugs less effective in horses than ruminants if administered at the 
same dose rates.
Protein binding influences the disposition (distribution and elimination) of a 
drug. Most drugs are bound mainly to plasma albumin but some are 
bound to other blood constituents such as alphar acid glycoprotein, 
lipoproteins and erythrocytes. The extent of binding varies with different 
species and is reversible. Protein binding also affects the intensity of the 
pharmacological effect. Only free, unbound drug is pharmacologically 
active and the bound drug is inert. Binding is a function of the 
concentration of the free drug. With increasing drug concentration and as 
the plasma protein binding sites become saturated, the amount of free 
drug increases slowly. This increase is rapid once saturation of the plasma 
proteins is attained. Multiple drug therapy can result in competition for 
plasma protein binding sites. One drug can displace the other from a 
binding site and this may result in toxic effects of the displaced drug as its 
free drug concentration rises. The pharmacological effect of a drug may 
also be enhanced in some disease states where the level of plasma 
albumin or the drug binding capacity of albumin is reduced. Extensive
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protein binding can decrease the amount of free drug that passes through 
the liver, thus reducing the rate of biotransformation and elimination. The 
rate of elimination is also slowed down in the kidneys as less free drug is 
removed from the serum by glomerular filtration. Most benzimidazole 
drugs have a plasma protein binding of less than 50% and a relatively 
high volume of distribution (Lanusse and Prichard, 1993a).However, the 
halogenated benzimidazoles, triclabendazole (Mohammed-Ali et a/., 1987; 
Hennessy et al., 1987) and lobendazole (Steel and Duwel, 1987) have 
been shown to have a strong binding to plasma proteins, which may 
contribute to their relatively long elimination rates and low volumes of 
distribution.
1.3.6 Effect of parasitism on the pharmacokinetics and metabolism of 
benzimidazoles
In ruminants, parasitic infection of the gastrointestinal tract has been 
shown to reduce the bioavailability of benzimidazoles.The bioavailability of 
fenbendazole and its metabolites in sheep experimentally infected with 
Ostertagia circumcincta and treated with fenbendazole was lower than 
that observed in uninfected sheep treated with the same dose of 
fenbendazole (Marriner et al., 1985). Similarly, the bioavailability of 
oxfendazole was reduced by 25% in goats infected with the same 
nematode compared to uninfected goats (Bogan et al., 1987). Parasitism 
of the gastrointestinal tract has been shown to cause elevated abomasal 
pH (Mostofa and McKellar, 1989; McKellar et al., 1990) and a constant 
stimulus for gastrin secretion leading to hypergastrinaemia and 
pronounced hyperplastic changes in the abomasal mucosal mass 
(Anderson et al., 1988). These changes may affect absorption and ionic- 
trap-mediated distribution of the different benzimidazole metabolites 
thereby, probably, altering the pharmacokinetic behaviour and expected 
efficacy of the anthelmintic drug. Furthermore, these changes may induce
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the development of side effects of the anthelmintic therapy. During bovine 
ostertagiasis, Murray (1969) reported increased permeability of the gastric 
mucosa to macromolecules. Gastrointestinal parasitism alters gut transit 
times which may also affect the pharmacokinetic behaviour of the 
benzimidazole anthelmintics. Elevated gastric pH causes reduced 
solubility of fenbendazole which would contribute to decreased 
bioavailability. Debackere and co-workers (1993) reported a decreased 
bioavailability of the benzimidazole prodrug febantel in lambs afflicted with 
ostertagiasis, as well as in those infected with Trichostrongylus 
colubriformis. The T. colubhformis infection caused reduced gut motility 
and mucosal villous atrophy which could affect drug absorption. Altered 
absorption accounts for the changes in bioavailability of the anthelmintics. 
During parasitism there may also be altered metabolism which could affect 
the pharmacokinetics of the anthelmintics. However, this is more likely to 
be as a result of liver damage due to liver fluke infection as the liver is the 
principal site of drug metabolism. It has been shown that the enzymatic 
activity of the hepatic microsomal cytochrome P-450-dependent 
monooxygenase system is depressed in rats (Tekwani et al., 1988) and 
sheep (Galtier et a/., 1986) that have been infected with Fasciola hepatica 
which could lead to altered drug metabolism and clearance (Tufenkji et 
a/., 1988). Parasitism may cause extensive liver damage leading to severe 
hypoalbuminaemia and this could affect the disposition of drugs which are 
extensively bound (>90%) to plasma proteins.
1.4 Metabolism of Benzimidazoles
Common to all the benzimidazole anthelmintics is the central structure, 
1,2-diaminobenzene (Fig 1.1). They differ from each other only at the 2 
and 5 substituent positions of the central structure. The benzimidazole 
compounds can be grouped as follows (Lanusse and Prichard, 1993b). 
Benzimidazole thiazolyl derivatives include thiabendazole (TBZ) and
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cambendazole (CBZ). Benzimidazole methylcarbamates have a 
substitution on position 5- of the benzene ring. They include parbendazole 
(PBZ), mebendazole(MBZ), flubendazole (FLBZ), ciclobendazole (CIBZ), 
oxibendazole (OBZ), luxabendazole (LBZ), albendazole (ABZ), 
ricobendazole (albendazole sulphoxide, ABZSO), fenbendazole (FBZ) and 
oxfendazole (OFZ). Halogenated benzimidazole thiols include 
triclabendazole (TCBZ) and probenzimidazoles include thiophanate (TPT), 
febantel (FBT) and netobimin (NTB).
The benzimidazole drugs are extensively metabolised in vivo with the 
parent drug being short-lived and metabolic products predominating in 
plasma and other tissues of the host (Delatour and Parish, 1986; Lanusse, 
and Prichard, 1993b). Mebendazole is an exception as it is poorly 
metabolised and is excreted unchanged mostly in faeces with only5-10% 
excreted in urine. Xenobiotic metabolism occurs primarily in the liver. 
However, extrahepatic tissues are also involved including blood plasma, 
kidneys and the gastrointestinal tract. Biotransformation usually results in 
metabolites that are more polar and less lipid soluble than the parent drug 
with reduced or no activity (Baggot, 1974). These reactions are usually 
biphasic. Phase I (non-synthetic) reactions are oxidation, reductions and 
hydrolysis and a number of enzyme complexes are involved of which the 
cytochrome P450 mediated mixed function oxidase (M.F.O.) system is the 
major one. Another important enzyme is the flavin-containing 
monooxygenase (FMO) system, which plays a major role in the oxidative 
metabolism of drugs and xenobiotics. Functional groups such as hydroxy, 
carboxy, amino and sulphydryl groups are introduced into organic 
substrates. The MFO comprises cytochrome P450, NADPH-cytochrome 
P450 reductase and lipid.
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Cytochrome P450 is a haemoprotein with iron protoporphyrin IX as the 
prosthetic group, and derives its name from the fact that the pigment
NH
R
Fig. 1.1 Chemical structure of the benzimidazole nucleus with the primary 
substituent positions shown.
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cytochrome exhibits a spectral absorbance maximum at 450nm when 
reduced and complexed with carbon monoxide. A common reaction 
catalysed by cytochrome P450 involves the incorporation of an oxygen 
atom, derived from “activated” molecular oxygen, into a generally lipophilic 
substrate. The necessary electrons to derive the reaction (a) are donated 
by NAD(P)H and cytochrome B5, and are catalysed by NADPH- 
cytochrome P450 reductase and cytochrome B5 reductase, respectively 
(Porter and Coon, 1991).
cytochrome P450
NADPH + H+ + 0 2+ RH ------------------- > NADP+ H20  + ROH (a),
NADPH-cytochrome
NADPH + H* + RH ------------------------------> NADP+H20  + ROH....(b), where
P450 reductase
RH is the oxidisable drug substrate and ROH is the hydroxylated 
metabolite. The reductases and cytochrome P450 are found in the smooth 
endoplasmic reticulum and in mitochondria.
Cytochrome P450 exists in multiple forms or isoenzymes that are 
classified, based on genes coding for specific P450 protein sequences 
(Nerbert et al., 1991), into a superfamily comprising families and sub­
families. A gene family comprises a cytochrome P450 sequence with 
usually less than 40% resemblance to that from any other family. 
Cytochrome P450 sequences within a sub-family in mammals show more 
than 55% resemblance (Witkamp, 1992). An arabic number represents the 
family, and this is followed by a letter denoting the sub-family, and an 
arabic number denoting a specific gene within a sub-family.
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NADPH-cytochrome P450 reductase is a flavin-containing enzyme 
(flavoprotein containing both FMN and FAD prosthetic groups) and is 
responsible for transferring reducing equivalents from NADPH +H+ to 
cytochrome P450 (see equation b).
The lipid component of the MFO system may be required for substrate 
binding, facilitation of electron transfer or providing a ‘template’ for the 
interaction of cytochrome P450 and NADPH-cytochrome P450 reductase 
molecules. However, its precise mode of action is yet to be confirmed 
(Gibson and Skett, 1994).
The FMO enzyme is found in many tissues but highest concentrations 
occur in the microsomal fraction of the liver. It uses either NADH or 
NADPH as a source of reducing equivalents in the oxygenation of many 
nucleophilic organic nitrogen and sulphur compounds (Gibson and Skett, 
1994), such as phenothiazines and sulphide benzimidazoles.
Phase II (synthetic, conjugation) reactions entail addition of sulphate 
groups, glucuronides, acetylation or methylation.
The most common reactions of the benzimidazoles occur at position 5- of 
the benzene ring. Phase I reactions, such as aliphatic and aromatic 
hydroxylations, N-, S- and O- dealkylations, N- and S-oxidations and 
reductive reactions, occur at this position. Another common reaction is the 
hydrolytic decarboxylation of the carbamate group at position 2- to form 
aminoderivatives (Gottschall et al., 1990). Metabolism of the benzene 
nucleus itself is rare e.g. 5-hydroxylation of thiabendazole, and N- 
methylation.
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Liver microsomal sulphoxidation is a common metabolic route for the 
commercially available thioether and sulphide benzimidazoles (ABZ, FBZ 
and TCBZ) (Fig. 1.2). and probenzimidazoles (FBT and NTB). They are 
extensively and rapidly metabolised to their sulphoxide and sulphone 
derivatives. Sulphoxidation is a reversible process (Marriner and Bogan, 
1980; 1981a, b; 1985; Mohammed Ali et al., 1987; Gyurik et al., 1981) 
resulting in an equilibrium between sulphide and sulphoxide, although the 
process favours metabolism towards the sulphoxide. Sulphonation follows 
sulphoxidation and is an irreversible and slower oxidative step resulting in 
a sulphone metabolite (Averkin et al., 1975). Two microsomal enzymatic 
systems are involved in sulphoxidation and sulphonation. However, FMO 
is the predominant system in ruminants, whereas in monogastrics both 
systems are equally involved (Delatour et al., 1994).
O o
II
- s - > -s- » -s -
II
Sulphide Sulphoxide
o
Sulphone
Fig. 1.2 Principal route of metabolism of the sulphide benzimidazoles (e.g. 
albendazole, fenbendazole and oxfendazole).
28
Another important metabolic route of the sulphide benzimidazoles is 
aromatic ring p-hydroxylation that leads to the formation of hydroxylated 
metabolites. These metabolites are excreted directly into the bile as free 
or conjugated metabolites and are therefore only detected to a limited 
extent, if at all, in the blood (Short et al., 1987a, b; 1988; Hennessy et al.,
1993).
Chirality
Using chiral HPLC Delatour et al. ( 1990a, b; 1991a, b) have 
demonstrated the presence of both enantiomers of benzimidazole 
sulphoxides in the plasma of various species following administration of 
prochiral sulphide parent molecule. Interspecies stereoselective 
differences for the benzimidazole sulphoxide exist and could be explained 
by different relative enzyme contributions. Both the FMO and the MFO 
systems act equally in rats, and probably in other monogastrics (man, dog, 
horse), while the FMO system is predominant in ruminants. FMO is 
product selective in favour of production of the (+)-sulphoxide while MFO 
specifically uses the (-)-sulphoxide as the substrate for sulphonation. The 
potency ratios (or eudismic ratios) of the enantiomeric pair are yet to be 
determined, and the importance of enantioselective pharmacokinetics of 
benzimidazole sulphoxide antipodes on their anti-parasitic effect is still 
unclear (Landoni et al., 1997).
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Aim of the study
The aim of this study was to examine the pharmacokinetic behaviour of 
the benzimidazole anthelmintic, fenbendazole, and to extend its systemic 
availability and thus hopefully increase its efficacy in the horse. The effect 
of food and/or the metabolic inhibitor, piperonyl butoxide, on co­
administration with fenbendazole on the bioavailability of the active 
metabolites (fenbendazole and fenbendazole sulphoxide) was 
investigated in the horse.
Chapter 2
Effect of food on the pharmacokinetics of fenbendazole with 
without piperonyl butoxide in horses
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2.1.1 Introduction
Fenbendazole is a broad spectrum sulphide benzimidazole anthelmintic 
used in dogs, cats, horses, sheep, goats, cattle and birds. Various 
attempts have been made to improve the efficacy of benzimidazole 
derivatives. In this study, the effect of administering fenbendazole with 
food was investigated on the relative bioavailability of the active 
metabolites in the horse. The time of feeding relative to oral drug 
administration has been shown to affect the bioavailability and absorption 
pattern of some drugs in horses. Feeding in horses was shown to 
decrease the mean plasma concentration and systemic availability of 
trimethoprim, but did not affect sulphadiazine absorption (Bogan et al., 
1984). Absorption for many drugs follows first-order kinetics such that an 
increased amount of drug is absorbed with increasing dose. An exception 
is that of absorption of fenbendazole in the dog as it was shown by 
McKellar et al. (1993) that the AUCs of parent fenbendazole and its 
sulphoxide metabolite do not significantly increase as the dose is 
increased from 10mg/kg up to 80mg/kg. The factors involved in the effect 
of food on drug absorption include an increase in stomach pH followed by 
degradation of pH-susceptible drugs (Boutin-Pannetier, et al., 1986), 
formation of chelates with calcium and iron, drug binding to 
macromolecules and irregularities in propulsion or gastrointestinal pH (pH 
partition hypothesis (Baggot, 1977)) in the presence of food.
One study carried out in dogs (McKellar et al., 1993) showed a significant 
increase in the systemic bioavailability of fenbendazole following its 
administration with food. In ruminants the systemic availability of 
fenbendazole is known to decrease when administered into the 
abomasum (Marriner and Bogan, 1981a). The rumen is thought of as a 
drug reservoir and it slows down the passage of digesta and extends the 
gut transit time of the drug. For an anthelmintic drug to be effective, it 
needs to achieve effective concentrations at the site of action. The 
different benzimidazoles are considered to have a similar mode of action 
and variations in their efficacy and spectrum of activity are associated with 
differences in pharmacokinetic behaviour. The efficacy and spectrum of 
activity will be determined by the concentration of the anthelmintic to 
which the parasite is exposed and the duration the parasite is exposed to 
toxic concentrations of the drug. Unfortunately, these concentrations are 
reduced rapidly in the horse due to the high activity of the hepatic 
microsomal associated metabolic pathways. Thus the ‘first pass’ effect 
may significantly decrease the systemic availability of orally administered 
drugs that are extensively metabolised. Fenbendazole is short-lived in 
plasma being extensively metabolised to its sulphoxide, sulphone and 
hydroxylated derivatives (Fig 2-1). The drugs that are active against 
helminths are the parent compound itself (FBZ) and the sulphoxide (SO) 
metabolite.
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Fenbendazole amine
Fenbendazole
Hydroxy fenbendazole
Fenbendazole sulphoxide Hydroxy fenbendazole sulphoxide
Fenbendazole sulphone Hydroxy fenbendazole sulphone
Figure 2-1. Major metabolic pathways fenbendazole
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Studies carried out in goats and sheep showed that coadministration of 
piperonyl butoxide (Fig 2-2) with fenbendazole results in inhibited 
metabolism of fenbendazole and thus potentiated anthelmintic action 
associated with the less oxidised moieties (Benchaoui and McKellar, 
1996). Piperonyl butoxide inhibits cytochrome P450- dependent oxidative 
metabolism by forming metabolic intermediates which bind covalently to 
the cytochrome P450 enzymes to form a complex with inhibitory effects on 
the MFO system (Franklin, 1977).
C ^ O C H ^ ^ O C H ^ ^ O C ^
Figure 2-2. Structure of piperonyl butoxide 
2.1.2 Aim
The aim of the present study was to determine the effect that the 
presence or absence of food has on the absorption of fenbendazole and 
whether the metabolic inhibitor, piperonyl butoxide, could be used to alter 
the biotransformation of fenbendazole in the horse, thus increasing the 
relative bioavailability of it’s active metabolites.
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2.2 Materials and methods
2.2.1 Animals
Six (06) ponies weighing 94 to 216.1 kg were used.
2.2.2 Experimental design
2.2.2.1 Experiment 1
The six ponies were not fed for 12 hours before the administration of the 
drugs. They were allocated into two groups of three animals each and 
were administered drugs in a two-way crossover design protocol. In the 
first phase one group received fenbendazole alone while the second 
group received both fenbendazole and piperonyl butoxide. In the second 
phase each group received the alternative treatment so that at the end of 
this experiment both treatments had been given sequentially to each pony 
used. A 4-week washout period was allowed between the experimental 
phases.
2.2.2.2 Experiment 2
The second experiment was carried out three months after the completion 
of the first experiment. The six ponies were not fed for 12 hours before the 
administration of drugs. However, they were each given half a bucket of 
coarse mix (cereal concentrates) one hour before drug administration and 
the other half just before drug administration. They were allocated into two
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groups of three animals each and were administered drugs in a two-way 
crossover design protocol as in the first experiment.
2.2.3 Drug administration and sampling procedure
Fenbendazole (Panacur, 2.5%, Hoechst Ltd.) was given at a fixed dose 
rate of 10mg/kg bodyweight administered orally by stomach tube. 
Piperonyl butoxide (90%) (Aldrich Chemicals) was administered by 
stomach tube at a fixed dose rate of 63mg/kg.
Blood samples were taken before drug administration and at 1, 2, 3, 4, 6, 
8, 12, 24, 32, 48, 72, and 96 hours thereafter. Samples were centrifuged 
to separate plasma which was then stored at -20 °C and analysed for 
the measurement of FBZ and its metabolites concentrations.
2.2.4 Drug analysis
Plasma samples were analysed by High Performance Liquid 
Chromatography following liquid phase extraction.
2.2.4.1 Standard preparation.
Stock solutions (100pg/ml) of pure standard fenbendazole, fenbendazole 
sulphoxide and fenbendazole sulphone (Hoechst Ltd., Frankfurt/Main, 
Germany) and albendazole (Sigma Chemical co, UK) were prepared using 
methanol (Rathburn Chemicals Ltd., UK) as a solvent. These were diluted
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to give 10 , 5 , 2.5 , 1 and 0.5 i^g/ml standard solutions for calibration and 
for adding to drug-free plasma samples to determine the recovery.
2.2.4.2 Extraction
Liquid phase extraction was the procedure used for fenbendazole (FBZ) 
and albendazole (ABZ). The method was adopted from that described by 
Marriner and Bogan (1980). To 1 ml plasma sample contained in a 10 ml- 
ground glass tube was added 200 jul of ammonium hydroxide (NH4OH , 
0.1N , pH 10 ) and 0.4 grams sodium chloride. This was vortexed for 30 
seconds and 6 ml of chloroform were added, the sample tubes were 
stoppered and shaken on a slow rotary mixer for 10 minutes. After 
centrifugation at 1700g, 4 ml of the organic phase were transferred to a 
thin-walled 10-ml conical glass tube and evaporated to dryness at 50°C 
under nitrogen. The residue was reconstituted with 200|il of 35% 
acetonitrile, placed in an ultrasonic water bath for 1 minute and finally 
processed on the HPLC system.
2.2.4.3 HPLC system
This comprised a solvent delivery pump (Spectra Physics SP4000) 
connected to a Capital HPLC nucleosil C18, 5pil column (15cm x 4.6mm) 
and a UV detector (Model SP 8450 Spectra Physics SP Focus, Burke 
Electronics Ltd., Glasgow, UK). The autosampler was a Spectra Physics 
SP AS 3000, the recorder a PC 1000 and the controller was a Model SN 
4000.
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The mobile phase was a mixture of acetonitrile-water to which glacial 
acetic acid (BDH Ltd., Pool, UK) (0.5% , v/v) was added. The solvent was 
pumped through the column in a linear gradient profile changing from 
35:65 (acetonitrile: water) to 55:45 in 8 minutes , 55:45 to 35:65 in 0.10 
minute and the former ratio was maintained for 4.9 minutes. The flow rate 
was 1.5ml/minute. The detector wavelength was at 292nm and the 
retention times for FBZSO, FBZS02 , FBZ and ABZ were 2.6, 4.1, 7.7 and
5.6 minutes respectively.
2.2.4.4 Recovery and precision
Recovery of the compounds from plasma to which the drugs had been 
added was evaluated by reference to peak areas resulting from direct 
injection of standard solutions. The precision of the extraction and 
chromatographic procedures was assessed by the coefficients of variation 
of replicate plasma samples to which known amount of drug had been 
added and analysed. Recoveries and coefficients of interassay variation 
are reported in Appendix A-1 and Limits of detection were 0.01 pg/ml for 
FBZSO , FBZS02 , FBZ and ABZ.
The concentrations of drug and metabolites in unknown samples were 
calculated by reference to plasma samples to which known amounts of 
drug and metabolites had been added and taken through the analytical 
procedure.
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2.2.5 Pharmacokinetic and statistical analysis
The individual data from each animal were analysed using non- 
compartmental model analysis with extravascular input (PC NONLIN 
version 4.0) (Metzler & Weiner, 1992).
The trapezoidal rule was used to calculate the area under the plasma 
concentration time curve (AUC0BS) and the area under the first moment 
curve (AUMCqbs) fr°m observed values. The mean residence time (MRT) 
is the ratio AUMCqbs/AUCobs-
Comparison of pharmacokinetic parameters for each metabolite obtained 
when animals were administered drugs after feeding or without feeding 
were made using Wilcoxon sign rank test. A Mann-Whitney U  test was 
used to determine the effect of administering fenbendazole with the 
metabolic inhibitor, piperonyl butoxide. Differences were considered 
significant when P < 0.05.
2.3 Results
Plasma concentrations of fenbendazole (Table 2-1 and 2-7, 
Appendices A-2, A-4, A-6 and A-8 ), fenbendazole sulphoxide ( Table 
2-3 and 2-9, Appendices A-10, A-12, A-14 and A-16) and fenbendazole 
sulphone (Table 2-5 and 2-11, Appendices A-18, A-20, A-22 and A-24) 
are plotted in Figs 2-1 and 2-4 (FBZ), 2-2 and 2-5 (FBZSO), and 2-3 
and 2-6 (FB ZS02).
Due to the large interindividual variations observed, there were no 
significant differences in any of the pharmacokinetic parameters of the 
metabolites obtained between administration of the drug without 
feeding and after feeding. Administration of fenbendazole with food 
resulted in an increased area under the plasma concentration time 
curve (37.5%) of the parent moiety, but the area under the first moment 
curve was reduced by 28.7%. Feeding produced higher mean 
maximum plasma concentrations of fenbendazole even though these 
were delayed by over 3 hours. For the sulphoxide metabolite, the AUC 
and the AUMC were much lower after feeding, and the MRT, Cmax, and 
tmax were decreased. The mean maximum plasma concentrations of 
0.02pg/ml for FBZ and FBZSO, and 0.04pg/ml for FB ZS02 attained 
were increased by 100 and 125% for the sulphide and sulphone but 
reduced by 50% in case of the sulphoxide following feeding. The AUC 
of fenbendazole parent drug was increased by 37.5% after feeding but 
the AUMC was reduced by 28.7 %. Feeding resulted in an elevation of 
the sulphone AUC by 13.9% but a reduction of the AUMC of 62.2%. 
However, the total AUC for the sulphide and the sulphoxide (active 
compounds) in unfed horses (1.19jig.h/ml) was twice as high as that in 
fed horses (0.59pg.h/ml).
Administration of fenbendazole with piperonyl butoxide without feeding 
produced significant differences in most of the pharmacokinetic
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Table 2-1. Plasma concentrations of fenbendazole (FBZ) (|ig/ml) following
administration of fenbendazole (10mg/kg) alone either with or without food
in horses.
Mean ± SEM
Time (h) FBZ without food 
(n=6)
FBZ with food 
(n=6)
0 0.002 ±0 .0017 0.000 ± 0.0000
1 0.011 ±0 .0062 0.020 ± 0.0045
2 0.016 ±0 .0063 0.027 ± 0.0057
3 0.014 ±0 .0072 0.026 ±0 .0107
4 0.011 ±0 .0066 0.025 ± 0.0085
6 0.012 ±0 .0050 0.020 ± 0.0057
8 0.008 ±0.0051 0.023 ± 0.0056
12 0.009 ± 0.0042 0.017 ±0 .0064
24 0.010 ±0 .0032 0.016 ±0 .0052
32 0.003 ±0 .0017 0.000 ± 0.0000
48 0.000 ± 0.0000 0.004 ± 0.0045
72 0.000 ± 0.0000 0.000 ± 0.0004
96 0.006 ± 0.0048 0.000 ± 0.0005
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Figure 2-1. Plasma concentrations of fenbendazole (FBZ) (jag/ml)
(mean±SEM) following administration of fenbendazole (10mg/kg) alone
(n=6) either with or without food in horses.
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Table 2-2. Pharmacokinetic parameters of fenbendazole (FBZ) following
administration of fenbendazole (10mg/kg) alone either with or without food
in horses.
Mean ± SEM
FBZ without food 
(n=6)
FBZ with food 
(n=6)
AUCqbs (|^g.h/ml) 
AUMCqbs (pg.h2/ml) 
MRT (h)
Cmax (ng/ml)
m^ax (^)
0.32 ±0 .107  
6.72 ± 1.644 
11.68 ±3 .288  
0.02 ± 0.006 
3.00 ± 1.826
0.44 ± 0.099 
4.79 ± 1.144 
11.40 ± 1.633 
0.04 ±0 .010  
6.50 ±3 .519
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Table 2-3. Plasma concentrations of fenbendazole sulphoxide (FBZSO)
(pg/ml) following administration of fenbendazole (10mg/kg) alone either
with or without food in horses.
Mean ± SEM
Time (h) FBZSO without food 
(n=6)
FBZSO with food 
(n=6)
0 0.000 ± 0.0000 0.001 ±0 .0013
1 0.000 ± 0.0000 0.003 ±0 .0014
2 0.000 ± 0.0000 0.007 ±0 .0013
3 0.009 ± 0.0063 0.007 ± 0.0026
4 0.010 ±0 .0065 0.010 ±0.0021
6 0.009 ± 0.0061 0.008 ± 0.0037
8 0.018 ±0 .0082 0.010 ±0 .0035
12 0.029 ± 0.0099 0.009 ± 0.0043
24 0.033 ±0 .0106 0.001 ± 0.0007
32 0.035 ±0 .0118 0.002 ± 0.0020
48 0.035 ±0 .0114 0.001 ±0 .0010
72 0.004 ± 0.0031 0.000 ± 0.0004
96 0.000 ± 0.0000 0.003 ± 0.0026
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Figure 2-2. Plasma concentrations of fenbendazole sulphoxide (FBZSO)
(pg/ml) (mean±SEM) following administration of fenbendazole (10mg/kg)
alone (n=6) either with or without food in horses.
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Table 2-4. Pharmacokinetic parameters of fenbendazole sulphoxide
(FBZSO) following administration of fenbendazole (10mg/kg) alone either
with or without food in horses.
Mean ± SEM
FBZSO without food 
(n=6)
FBZSO with food 
(n=6)
A U C qbs (pg h/ml) 
A U M C qbs (pg.h2/ml) 
MRT (h)
Cmax (pg/ml)
m^ax (h)
1.87 ±0 .599  
64.69 ±21 .494  
22.94 ± 7.352 
0.03 ±0 .0132  
22.67 ± 7.843
0.15 ±0 .059  
1.38 ±0 .565  
7.53 ± 1.279 
0.01 ± 0.004 
3.67 ± 0.954
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Table 2-5. Plasma concentrations of fenbendazole sulphone (FB ZS02)
(jug/ml) following administration of fenbendazole (10mg/kg) alone either
with or without food in horses.
Mean ± SEM
Time (h) FBZS02 without food FBZS02 with food
(n=6) (n=6)
0 0.000 ± 0.0000 0.004 ± 0.0025
1 0.003 ±0 .0018 0.0023 ± 0.0055
2 0.023 ±0 .0112 0.038 ± 0.0079
3 0.030 ±0 .0160 0.042 ± 0.0095
4 0.030 ±0 .0160 0.062 ±0 .0175
6 0.030 ±0 .0165 0.052 ±0 .0155
8 0.029 ±0 .0166 0.057 ±0 .0125
12 0.021 ±0 .0077 0.047 ± 0.0090
24 0.018 ±0 .0056 0.027 ± 0.0032
32 0.015 ±0 .0059 0.016 ±0 .0037
48 0.011 ±0 .0045 0.020 ± 0.0084
72 0.008 ± 0.0052 0.004 ±0 .0013
96 0.004 ± 0.0033 0.0009 ± 0.0036
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Figure 2-3. Plasma concentrations of fenbendazole sulphone (FBZS02)
(pg/ml) (mean±SEM) following administration of fenbendazole (10mg/kg)
alone (n=6) either with or without food in horses.
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Table 2-6. Pharmacokinetic parameters of fenbendazole sulphone
(FB ZS02) following administration of fenbendazole (10mg/kg) alone either
with or without food in horses.
Mean ± SEM
FBZS02 without food 
(n=6)
FBZS02 with food 
(n=6)
A llC 0Bs (pg.h/ml) 
AUMCqbs (pg h2/ml) 
MRT (h)
Cmax (pg/ml)
m^ax (l"0
1.29 ±0 .493
44.50 ±22 .145  
30.86 ± 5.999 
0.04 ±0 .016
15.50 ±7 .329
1.47 ±0 .186  
27.25 ± 3.658 
18.77 ±1 .698  
0.09 ±0 .015  
4.83 ± 0.980
Table 2-7. Plasma concentrations of fenbendazole (FBZ) (pg/ml) following
administration of fenbendazole (10mg/kg) in combination with piperonyl
butoxide (PB) (63mg/kg) either with or without food in horses.
Mean ± SEM
Time (h) FBZ and PB without 
food 
(n=6)
FBZ and PB with food 
(n=5)
0 0.002 ± 0.0023 0.001 ± 0.0009
1 0.028 ± 0.0090 0.083 ± 0.0265
2 0.054 ±0.0174 0.118 ±0 .0364
3 0.068 ± 0.0238 0.137 ±0 .0443
4 0.068 ±0.0216 0.260 ± 0.0771
6 0.083 ± 0.0273 0.180 ±0 .0610
8 0.096 ±0.0199 0.355 ±0 .1316
12 0.135 ±0.0163 0.278 ±0 .1189
24 0.133 ±0.0245 0.157 ±0 .0553
32 0.032 ± 0.0076 0.005 ± 0.0036
48 0.000 ± 0.0000 0.035 ± 0.0251
72 0.000 ± 0.0000 0.000 ± 0.0000
96 0.000 ± 0.0000 0.000 ± 0.0000
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Figure 2-4. Plasma concentrations of fenbendazole (FBZ) (|ug/ml) 
(mean±SEM) following administration of fenbendazole (10mg/kg) in 
combination with piperonyl butoxide (PB) (63mg/kg) either with or without 
food in horses.
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Table 2-8. Pharmacokinetic parameters of fenbendazole (FBZ) following
administration of fenbendazole (10mg/kg) in combination with piperonyl
butoxide (PB) (63mg/kg) either with or without food in horses.
Mean ± SEM
FBZ and PB without 
food 
(n=6)
FBZ and PB with food 
(n=5)
AUCqbs (pg.h/ml) 
AUMCqbs (pg.h2/ml) 
MRT (h)
Cmax (pg/ml)
m^ax (h)
3.51 ±0.401  
61.79 ±8 .453
17.51 ±1 .450  
0.16 ±0 .015  
17.00 ±3 .256
5.81 ± 1.961 
76.72 ± 25.094 
12.63 ± 1.965 
0.37 ±0 .104  
13.60 ±4 .308
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Table 2-9. Plasma concentrations of fenbendazole sulphoxide (FBZSO) 
(jug/ml) following administration of fenbendazole (10mg/kg) in combination 
with piperonyl butoxide (PB) (63mg/kg) either with or without food in 
horses.
Mean ± SEM
Time (h) FBZSO and PB without 
food (n=6)
FBZSO and PB with 
food 
(n=5)
0 0.000 ± 0.0000 0.001 ± 0.0006
1 0.000 ± 0.0000 0.014 ±0 .0082
2 0.000 ± 0.0000 0.021 ±0 .0126
3 0.004 ± 0.0024 0.031 ±0 .0188
4 0.006 ± 0.0029 0.065 ± 0.0359
6 0.010 ±0 .0053 0.052 ± 0.0265
8 0.018 ±0 .0072 0.116 ±0 .0583
12 0.027 ± 0.0069 0.117 ± 0.0717
24 0.030 ± 0.0073 0.060 ± 0.0242
32 0.010 ±0 .0077 0.001 ± 0.0006
48 0.005 ± 0.0032 0.010 ±0 .0059
72 0.000 ± 0.0000 0.000 ± 0.0000
96 0.000 ± 0.0000 0.000 ± 0.0000
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Figure 2-5. Plasma concentrations of fenbendazole sulphoxide (FBZSO) 
(pg/ml) (mean+SEM) following administration of fenbendazole (10mg/kg) 
in combination with piperonyl butoxide (PB) (63mg/kg) either with or 
without food in horses.
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Table 2-10. Pharmacokinetic parameters of fenbendazole sulphoxide 
(FBZSO) following administration of fenbendazole (10mg/kg) in 
combination with piperonyl butoxide (PB) (63mg/kg) either with or without 
food in horses.
Mean ± SEM
FBZSO and PB without 
food (n=6)
FBZSO and PB with 
food 
(n=5)
AUC0Bs (ng.h/ml) 
AUMCqbs (pg.h2/ml) 
MRT (h)
Cmax (^g/ml) 
tmax (h)
0.82 + 0.2178 
19.15 ±6 .5593  
21.05 ±2 .5287  
0.04 ± 0.0038 
19.00 ±3.2558
2.08 ± 0.992 
28.97 ± 12.970 
13.56 ±2 .437  
0.13 ±0 .067  
14.40 ± 4.118
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Table 2-11. Plasma concentrations of fenbendazole sulphone (FBZS02) 
(pg/ml) following administration of fenbendazole (10mg/kg) in combination 
with piperonyl butoxide (PB) (63mg/kg) either with or without food in 
horses.
Mean ± SEM
Time (h) FBZS02 and PB 
without food (n=6)
FBZS02 and PB with 
food (n=5)
0 0.000 ± 0.0000 0.002 ± 0.0024
1 0.000 ± 0.0002 0.002 ± 0.0021
2 0.002 ±0.0018 0.003 ±0 .0019
3 0.000 ± 0.0000 0.003 ±0.0019
4 0.003 ± 0.0030 0.006 ± 0.0040
6 0.000 ± 0.0000 0.009 ± 0.0025
8 0.010 ±0 .0059 0.016 ±0 .0034
12 0.012 ±0 .0074 0.033 ± 0.0073
24 0.046 ±0 .0119 0.102 ±0.0341
32 0.035 ±0 .0145 0.015 ±0.0061
48 0.006 ± 0.0031 0.071 ± 0.0340
72 0.007 ± 0.0045 0.002 ±0 .0012
96 0.002 ± 0.0023 0.002 ±0 .0014
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Figure 2-6. Plasma concentrations of fenbendazole sulphone (FBZS02) 
(jLtg/ml) (mean±SEM) following administration of fenbendazole (10mg/kg) 
in combination with piperonyl butoxide (PB) (63mg/kg) either with or 
without food in horses.
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Table 2-12. Pharmacokinetic parameters of fenbendazole sulphone 
(FB ZS02) following administration of fenbendazole (10mg/kg) in 
combination with piperonyl butoxide (PB) (63mg/kg) either with or without 
food in horses.
Mean ± SEM
FBZSO2 and PB 
without food (n=6)
FBZS02 and PB with 
food (n=5)
A U C qbs (ug h/ml) 
A U M C qbs (pig h2/ml) 
MRT (h)
Cmax (fig/ml)
m^ax (^)
1.29 ±0 .273  
45.26 ± 13.192 
28.10 ±7 .106  
0.05 ±0 .013  
20.00 ± 5.367
1.44 ±0 .328  
30.33 ± 7.950 
20.19 ± 1.718 
0.11 ±0 .028  
21.60 ±2 .400
parameters of the active metabolites (P<0.05). There was no statistical 
evidence of any difference in those of the sulphone metabolite except 
for the tmax. AUC, AUMC and Cmax values for fenbendazole were 
significantly increased following administration of fenbendazole and 
piperonyl butoxide after feeding. For the sulphoxide and sulphone 
metabolites only the tmax (and also Cmax for sulphoxide) values were 
significantly increased following administration of piperonyl butoxide. 
The inhibitor increased the AUC, AUMC and Cmax values for the parent 
drug 10 , 8 and 7 times, respectively, but decreased the same 
parameters for fenbendazole sulphoxide by 56.1, 70.4 and 50% 
respectively, in the unfed horses. It only had a slight effect on AUC and 
AUMC values of the sulphone metabolite (0.0 and 1.7% increment only 
respectively). In the fed horses , the fenbendazole AUC, AUMC and 
Cmax were increased by 12.2, 15 and 8.25 times, respectively, with 
piperonyl butoxide pre-treatment. The MRT was also slightly increased 
(10.8%). In contrast to the situation in the unfed horses, the sulphoxide 
pharmacokinetic parameters in the fed horses were markedly increased 
by approximately 13, 20, and 12 times for the AUC, AUMC and Cmax 
values, respectively, with piperonyl butoxide pre-treatment. The MRT 
was increased by 80% in this case. In unfed horses, the total AUC for 
the sulphide and the sulphoxide metabolite registered a more than 
three-fold increase after administration of piperonyl butoxide. In fed 
horses, the increase was even greater (more than 13 times).
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2.4 Discussion
Fenbendazole was extensively metabolised to the sulphoxide and the 
sulphone metabolites in the horse with low amounts of the parent drug 
measured in the plasma and higher amounts of the metabolites. The 
amounts of the sulphoxide metabolite were found to be very low in relation 
to the sulphone in the fed horses, and this supports the work of Marriner 
and Bogan, (1985). This is attributed to the high rate of sulphonation in 
this species. Feeding was shown to affect the kinetics of the 
benzimidazole anthelmintics in the horse. The mean maximum plasma 
concentration of fenbendazole was increased by 100% after feeding but 
the time taken to reach Cmax was more than doubled. The persistence of 
fenbendazole in the plasma was only slightly affected (reduced by 17 
minutes). An interesting finding in the unfed horses was the higher 
amounts (as indicated by the areas under the curve) of the sulphoxide as 
compared to the sulphone, whereas in the fed horses the situation was 
the opposite. It may be that feeding slows the rate of absorption of 
fenbendazole, and that most of the fenbendazole that is absorbed is 
converted to the sulphoxide and then immediately converted to the 
sulphone. In unfed horses, fenbendazole could be absorbed at a faster 
rate such that there is more substrate for sulphoxidation per unit time and 
this reaction is occurring more rapidly than sulphonation. Hence, the 
higher sulphoxide amounts in unfed horses. The increased time to Cmax of 
fenbendazole suggests a reduced rate of absorption with feeding and the 
shorter MRT of the sulphoxide compared to the sulphone is probably due
to a faster elimination (e.g. conversion to sulphone), Hence the higher 
sulphone amounts in fed horses. The sulphoxide MRT in unfed animals 
was also shorter (by 7.92 hours) than for the sulphone but not as much as 
that observed in fed horses. Thus feeding would reduce the overall 
amount of active drugs and increase the persistence of the inactive 
sulphone in the blood.
Fenbendazole might be extensively bound to food, and this would 
inevitably delay the absorption rate. However, it’s MRT was not much 
affected. The double peaks observed in the drug plasma concentration­
time profiles (see Figs 2-1 and 2-4) suggest an uneven pattern of 
absorption. Some of the administered drug may have been absorbed 
directly from the intestine but the bound drug may have been absorbed at 
a later stage in the colon and /or caecum as it was being released by 
fermentative digestion. The slightly decreased mean residence time of 
fenbendazole with feeding does not, however, support this suggestion. 
Double peaks could also arise from the uneven absorption of drug along 
the different segments of the Gl tract, and from drugs that undergo 
gasteroenteric recycling.
Piperonyl butoxide produced striking effects on the pharmacokinetics of 
fenbendazole when administered with it. The plasma concentration of 
fenbendazole was increased dramatically with metabolic inhibition as 
evidenced by the higher amount of drug in the body (high AUC and AUMC
values) and higher mean maximum plasma concentrations. An even 
higher plasma concentration was achieved when the horses were 
administered drug with food. Higher tmax values were required to reach the 
increased concentrations and in case of fenbendazole this was at 17 
hours post treatment, an increase of 14 hours compared to that without 
pre-treatment with piperonyl butoxide. The sulphoxide AUC and AUMC 
values were reduced with inhibition in the unfed horses but the AUC was 
higher in fed animals pre-treated with the inhibitor. The lower sulphoxide 
areas under the curve were probably due to inhibition of the cytochrome 
P-450 enzyme system thereby maintaining higher plasma sulphide 
amounts. The high sulphone metabolite concentrations observed with 
piperonyl butoxide pre-treatment were not expected. It would seem logical 
to assume that the lower plasma concentration of the sulphoxide would 
leave little substrate for sulphonation. In addition, an inhibition of 
sulphonation was also expected.
In conclusion, feeding in horses reduces the relative plasma concentration 
of the active moieties of fenbendazole and it is anticipated that this would 
reflect reduced efficacy of the drug. Fenbendazole should therefore be 
administered without food in horses. The coadministration of the S- 
oxidation-impairing piperonyl butoxide markedly improved the plasma 
concentration of fenbendazole and this possible method of improving its 
anthelmintic efficacy deserves further investigation.
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Chapter 3
The in vitro metabolism of benzimidazole anthelmintics
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3.1 Introduction
Metabolism of xenobiotics occurs mainly in the liver but also occurs in a 
number of other tissues (e.g. gastrointestinal tract, kidneys). Hepatic 
subcellular fractions are useful in vitro models for the study of 
benzimidazole compounds and their biotransformation pathways under 
strictly controlled conditions. Furthermore, in vitro studies are less costly 
compared to in vivo studies that require animal purchase, care and 
maintenance (Van’t Klooster, 1992). In addition, the number of 
experimental animals used in xenobiotic biotransformation studies and 
toxicity studies may be minimised through the use of in vitro experiments.
In the present study, the in vitro inhibition of metabolism of fenbendazole 
in equine liver was investigated and the effect of piperonyl butoxide, a 
cytochrome P450 inhibitor, was determined. A similar in vitro study was 
undertaken by Benchaoui and McKellar, (1996), using rat liver 
microsomes. Evidence from in vitro studies indicates that the 
sulphoxidation of fenbendazole involves both the flavin monooxygenase 
and the cytochrome P450 systems (Benchaoui and McKellar, 1996). In 
vitro studies done using rat liver microsomes showed that fenbendazole 
metabolites, particularly the sulphone and hydroxylated metabolites, but 
not the sulphoxide metabolite, also acted to inhibit cytochrome P450 
enzyme activity (Murray et a l , 1992). Oxfendazole (which is the same as 
fenbendazole sulphoxide) has been shown to induce cytochrome P450, 
more specifically the isoenzyme P450 IA2 and it’s corresponding
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monooxygenases, in rabbit liver microsomes (Gleizes et al., 1991a) and 
rabbit liver hepatocytes (Gleizes eta/., 1991b).
3.2 Materials and methods
3.2.1 Liver microsome preparations
3.2.1.1 Chemicals
The chemicals used for the NADPH-generating cofactor solution were as 
follows: Trizma hydrochloride, Trizma base, isocitrate dehydrogenase, 
nicotinamide adenine dinucleotide phosphate (NADP), niacinamide (or 
nicotinamide ) and trisodium isocitrate, all obtained from Sigma Chemical 
Ltd. (U K ); and MgCI2 from BDH Chemicals Ltd. (Poole, UK).
The standard compounds used were albendazole and oxfendazole from 
Sigma Chemicals Ltd. (UK), fenbendazole, fenbendazole sulphoxide 
fenbendazole sulphone from Hoechst Ltd. (Frankfurt/ Main, Germany) and 
90% piperonyl butoxide (Aldrich Chemicals Ltd., UK). Solvents used in this 
experiment were methanol (Rathburn Chemicals Ltd., UK) and varying 
proportions of acetonitrile (Rathburn Chemicals Ltd., UK) with water and 
acetic acid (BDH Chemicals Ltd., Poole, UK) and dimethylsulphoxide 
(DMSO) ( BDH Chemicals Ltd., Poole, UK), which was used to dissolve 
standard drugs to be added to the incubation mixture.
Chemicals used for the isolation of microsomes include 0.9% sodium 
chloride and 1.15% potassium chloride from BDH Chemicals Ltd., Poole, 
UK, and Tris buffer in 20% glycerol ( Sigma Chemical Ltd., UK).
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The materials used included the Beckman J2-21 refrigerated centrifuge 
and the Beckman L8-70 refrigerated ultracentrifuge (California, USA), an 
Ultra-turrax ( Janke & Kunkel GmbH & Co., Germany), and Potter- 
Elvehjem homogeniser.
Microsomal protein was measured using the Coomassie® protein Assay 
Reagent (Pierce Chemical Co, Rochford, UK) with Bovine Serum Albumin 
(BSA) standard.
3.2.1.2 Isolation
The liver microsomes were prepared from livers obtained from six (6) 
different horses ( A, B, C, D, E, and F). The different weights of the liver 
portions used are shown in Appendix B-1. Shortly after a horse was killed, 
the liver was removed, and perfused with ice cold saline (0.9%, NaCI 
solution) through the hepatic veins. The liver portion was then drained of 
excess moisture and weighed. All procedures were performed at 0-4 °C. 
The liver tissue was placed in 300 ml of 1.15% KCI solution and finely 
chopped before homogenisation using a Potter-Elvehjem homogeniser. 
Several passages of the teflon pestle were necessary to disrupt the tissue. 
The liver homogenate was centrifuged for 20 minutes at about 9000g in a 
Beckman J2-21 refrigerated centrifuge to clean the tissue (removal of cell 
debris, nuclei and mitochondria). The floating fat layer was removed with a 
pasteur pipette, and the supernatant decanted in 6 Beckman Ultra-Clear 
tubes (California, USA). The tubes were centrifuged at 10500g for 75 
minutes in a Beckman L8-70 refrigerated ultracentrifuge. After discarding
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the cytosolic fraction (supernatant), the microsomal pellet was 
resuspended in 60ml of 0.1M Tris-phosphate buffer (pH 7.4) containing 
20% (v/v) glycerol using an Ultra-turrax. The microsomal suspensions 
(final volumes shown in Appendix B-2) were then stored at -70 °C. until 
used for incubation assays. Diluted ( x500) microsomal suspensions were 
used in the determination of total protein. The protein content was 
determined using the Micro-assay procedure of Coomassie® Protein 
Assay Reagent. The assay is based on the absorbance shift from 465 to 
595nm that occurs when Coomassie Brilliant Blue G-250 binds to proteins 
in an acidic solution. A standard curve using BSA was run with each 
assay. This is a strongly recommended procedure as the colour response 
is non-linear over a wide range of protein concentration. A review of the 
protein content measurement procedure is given by Davies (1988). A 
determination of cytochrome P450 concentrations was not done.
3.2.1.3 Drug incubation
Incubations were carried out in a shaking water bath at 37 °C for a period 
of 2 hours, after which they were stopped by placing tubes with the 
reaction mixture in boiling water for 2 minutes. This was immediately 
followed by freezing at -20 °C until analysis. Ten-ml glass test tubes were 
used. One assay of an incubation mixture contained 4mg of microsomal 
protein suspension, 5jnl of test drug (fenbendazole, or fenbendazole 
sulphoxide) alone or with 5pl of piperonyl butoxide (PB), and 1.0ml of the 
co-factor solution. The precise amounts are shown in Appendix B-1 and
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B-2. Incubations were done in triplicate. Tubes without microsomes were 
used as controls for possible nonenzymatic drug conversion. Piperonyl 
butoxide was used at a constant concentration of 50pM. Fenbendazole 
and fenbendazole sulphoxide concentrations used were 5, 10, 25 and 
50pM.
3.3 Drug analysis
3.3.1 Extraction
Fenbendazole and it’s respective metabolites were analysed in a similar 
fashion to the procedure outlined in section 2.2.4. The drug extraction 
method involved the use of total samples of the incubation mixture and 
each incubation tube was rinsed with 1.0ml acetonitrile, which was also 
included for the extraction.
3.3.2 HPLC system
This is as described in section 2.2.4.3 except for the following 
modifications. The column used was a Genesis nucleosil C18, 4pl, 
column(15cm X 4.6cm) (Jones Chromatography).
The mobile phase was pumped through the column in a linear gradient 
profile changing from 40:60 (acetonitrile: water) to 50:50 in 4 minutes, to 
70:30 in 8 minutes and this was maintained for up to 12 minutes running 
time. A wash of the column with 99.5% acetonitrile and 0.5% acetic acid 
for 7.90 minutes was incorporated between each run, after which the
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mobile phase composition returned to 40:40 at 20.10 minutes run time. 
The column was allowed 10 minutes to equilibrate. Thus each run was 
quite long (30 minutes) because of the wash, which was necessary to 
avoid too many irrelevant dirt peaks from being eluted. The retention times 
were approximately 10.10, 3.78 and 5.83 minutes for fenbendazole, 
sulphoxide and sulphone respectively, and 7.78 minutes for the 
albendazole standard.
3.4 Statistical analysis
The extent of conversion and the amount of unchanged drug, with and 
without metabolic inhibition were compared by analysis of variance. 
Results were considered significant when P<0.05.
3.5. Results
The composition of the co-factor solution needed to generate NADPH 
during incubation of the (FBZ, FBZSO) with hepatic microsomes is given 
in Appendix B-1. The microsomal protein content of the different equine 
livers used is given in appendices B-2, B-3 and B-4.
Incubation done without microsomes resulted in slight sulphonation of the 
FBZSO (Oxfendazole) parent drug (1.4%) (see Appendix B-5)
Incubation of the benzimidazole drugs resulted in formation of their 
sulphone and sulphoxide metabolites (for FBZ) and sulphone and 
sulphide metabolites (for FBZSO). Hydroxylated metabolites were not 
measured in this study.
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The extent of metabolism of fenbendazole was 11, 30.7, 3.56 and 25.7%  
for the 5, 10, 25 and 50pM substrate concentrations used (Appendix B-7, 
Figs 3.1, 3.2, 3.3 and 3.4) respectively. Upon addition of the cytochrome 
P450 inhibitor, piperonyl butoxide (PB), the extent of conversion of 
fenbendazole was reduced by 29.6, 38.4, 22.9 and 16.9% for 5 and 10 
and 25 and 50pm substrate concentrations respectively. The extent of 
metabolism of FBZSO was also reduced by over 20% on co­
administration of PB at 10 and 25pm concentrations (Appendix B-6). 
Despite these apparently large differences between metabolism of drug 
with and without PB, no statistical significance could be inferred due to the 
large interindividual variations. This was also the case for studies on 
sulphonation and sulphoxidation.
The effect of PB on sulphonation for FBZ was variable for the different 
concentrations and the different livers used (Appendix B-11, Figs 3.5, 3.6, 
3.7 and 3.8) with lower substrate concentrations (5 and 10pm) resulting in 
increased sulphone formation and higher concentrations (25 and 50pm) 
resulting in reduced production. The oxfendazole substrate yielded a 
reduced amount of sulphone of generally more than 70% following 
addition of PB (Appendix B-8, Figs 3.9, 3.10, 3.11 and 3.12.). It was also 
observed that decreasing the substrate-PB ratio increased the extent of 
sulphonation of FBZSO, with maximum sulphonation achieved at the ratio 
of 1:5 (see Appendix. B-8 and B-11)
Reduction of FBZSO (oxfendazole) substrate to sulphide was also 
decreased (by over 90%) upon addition of PB (Appendix B-9). The 
amount of FBZ formed after FBZSO metabolism was generally greater 
than the amount of FBZS02 formed (i.e. reduction > sulphonation). 
However following addition of PB, the two metabolites were formed in 
approximately equal ratios.
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Piperonyl butoxide drastically iowered (by more than 90%) the 
sulphoxidation of FBZ (Appendix B-10, Figs 3.5, 3.6, 3.7 and 3.8). In the 
absence of the inhibitor, the extent of sulphonation was less than the 
extent of sulphoxidation, but the two processes produced more or less 
equal amounts of metabolite following addition of inhibitor, thereby 
increasing the sulphonation: sulphoxidation ratio.
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Figure 3-1. Amount of unchanged drug remaining in the 
microsomal reaction mixture after incubation of BZ (5pM) 
with (BZ + PB ) and without (control) piperonyl butoxide 
(n=4).
■  FBZ120
□  FBZSO
100
T 3
-§ 60 -
a .  o
O  ^c 0J o ^
CJ)
CONTROL BZ + PB
Figure 3-2. Amount of unchanged drug remaining in the 
microsomal reaction mixture after incubation of BZ (10pM) 
with (BZ + PB) and without (control) piperonyl butoxide 
(n=4).
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Figure 3.3 Amount of unchanged drug remaining in the 
microsomal reaction mixture after incubation of BZ (25|jM) 
with (BZ + PB) and without (control) piperonyl butoxide 
(n=4).
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Figure 3.4 Amount of unchanged drug remaining in the 
microsomal reaction mixture after incubation of BZ (50pM) 
with (BZ + PB) and without (control) piperonyl butoxide
(n=4).
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Figure 3.5 Effect of piperonyl butoxide (PB) (50pM) on 
microsomal fenbendazole (5pM) metabolism in equine liver
Figure 3.6 Effect of PB (50pM) on microsomal
fenbendazole (10pM) metabolism in equine
liver (n=4).
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Figure 3.7 Effect of PB (50(jM) on microsomal 
fenbendazole (25jjM) metabolism in equine liver (n=4).
■ FBZSO
□ FBZS02
3 -
a; 2 "
1 -
FBZ FBZ + PB
Figure 3.8 Effect of PB (50(jM) on microsomal
fenbendazole (50|jM) metabolism in equine
liver (n=4).
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Figure 3.9 Effect of PB (50|jM) on microsomal fenbendazole 
sulphoxide (5pM) metabolism in equine liver (n=3).
Figure 3.10 Effect of PB (50pM) on microsomal fenbendazole
sulphoxide (10pM) metabolism in equine liver (n=4).
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Figure 3.11 Effect of PB (50pM) on microsomal fenbendazole 
sulphoxide (25pM) metabolism in equine liver (n=4).
Figure 3.12 Effect of PB (50pM) on microsomal fenbendazole
sulphoxide (50pM) metabolism in equine liver (n=4).
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3.6 Discussion
Fenbendazole is known to be extensively metabolised in vivo to it’s 
sulphoxide, sulphone and hydroxylated metabolites (Short et a l, 1988). In 
vivo studies conducted with fenbendazole do not quite achieve the 
extensive metabolism observed in the in vivo studies in which only a small 
fraction of the parent compound remains in the blood. Studies done using 
rat hepatic microsomes yielded only 16% conversion of fenbendazole into 
metabolites (Benchaoui and McKellar, 1996). In the present study, the 
metabolism of fenbendazole was found to be variable with different 
substrate concentrations and individuals; substrate: PB ratios of 1:5 and 
1:1 produced the highest degree of metabolism (30.7 and 25.7%, 
respectively). The present in vitro study was complicated by the large 
interindividual variations in results. Microsomal protein concentrations 
(mg) per gram of liver were below the usual 20mg/g liver (Gibson and 
Skett, 1994) found with other species and this could have affected the 
extent and rate of metabolism of the parent drugs. The large 
interindividual variations could be due to one, or several of, the many 
factors that may affect drug metabolism. For instance, the liver is a 
heterogenous organ, with differences in drug metabolism between the 
centrilobular and periportal areas (Gibson and Skett, 1994), and the 
section from which the sample is extracted may be of relevance in drug 
metabolism studies. In addition, there was inadequate knowledge about
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the clinical history (e.g. age, whether diseased or not, and previous drug 
treatment) of the horses used in the present study.
The cytochrome P450 inhibitor, piperonyl butoxide, decreased the extent 
of metabolism of fenbendazole. Sulphoxidation was observed to have 
been drastically reduced with the addition of the inhibitor and this may 
explain the lower amounts of sulphone formed at least with the higher 
sulphide substrate concentrations. It is not clear why the lower 
concentrations lead to increased expression of sulphonation as the 
sulphone: sulphoxide ratio in all cases following addition of PB was found 
to have increased, indicating that PB affected both sulphoxidation and 
sulphonation. The average sulphone to sulphoxide ratio was 0.045 before 
and 1.275 after addition of PB. Incubation of hepatic microsomes with 
fenbendazole sulphoxide revealed a reduction in sulphonation following 
co-administration with PB indicating that the lower sulphone metabolite 
concentrations produced were not a result of lower sulphoxide 
concentrations.
In the present in vitro study, piperonyl butoxide reduced the extent of 
metabolism of fenbendazole by up to 38.4% and that of oxfendazole by 
over 20%. Even though, the results of in vitro cannot be adequately 
extrapolated to the results of in vivo studies, similar changes in metabolic 
inhibition would be anticipated. The in vivo studies reported in chapter 2
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revealed much greater changes in the metabolic inhibition by piperonyl 
butoxide than the changes observed with the in vitro studies.
In comparison to the FMO inhibitor, methimazole (MTZ), greater metabolic 
inhibition in vivo appears to have been achieved with piperonyl butoxide. 
In vivo studies carried out in sheep by Lanusse et al. (1995) with MTZ 
showed less metabolic inhibition of fenbendazole parent drug relative to 
the in vivo studies in horses reported in chapter 2. The FBZ parent drug 
AUC value was only increased by 113% with MTZ as compared to the ten­
fold increase with PB. The ratio of the AUC values (FBZ: FBZSO) was 
slightly increased (from 0.12 to 0.16) with MTZ administration in sheep as 
compared to a much larger increase ( from 0.17 to 4.28) with piperonyl 
butoxide in horses. However, the fact that different species were used 
needs to be considered since wide differences in the rate of xenobiotic 
metabolism exist between horses and sheep. Horses have a more rapid 
rate of metabolism of some drugs than sheep. In addition to the species 
differences, a direct comparison is difficult to make due to the different 
dosage regimens administered- 5mg/kg FBZ and 3mg/kg MTZ in sheep 
and 10mg/kg FBZ and 63mg/kg PB in horses. It may be that the greater 
metabolic inhibition observed with PB in horses than that observed with 
MTZ in sheep was due, or at least partially, to the higher proportion of the 
inhibitor relative to the benzimidazole. Methimazole had little effect on the 
sulphoxide metabolite pharmacokinetics, whereas PB caused a significant 
decrease in the FBZSO AUC and Cmax values in the unfed horses and an
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increase of the same parameters in the fed horses. Piperonyl butoxide 
had little effect on the sulphone metabolite AUC and MRT values, and 
both inhibitors delayed the tmax values of the sulphone metabolite. The 
observed differences with the two inhibitors may also be explained by the 
difference in the hepatic enzyme contributions in the fenbendazole 
oxidative steps in the two species. Furthermore, MTZ is a substrate for the 
FMO system and competition with FBZ for binding sites on the enzyme 
system may be responsible for changes observed in the disposition 
kinetics of the sulphide and sulphoxide metabolites, as was seen with 
albendazole and albendazole sulphoxide in ruminants (Lanusse and 
Prichard, 1992a, b). In ruminants, MTZ is most likely to affect 
sulphoxidation, since the FMO system is the predominant system in these 
species (Delatour et a/., 1994). However, the involvement of MTZ with 
cytochrome P450 which is mostly responsible for sulphonation in 
ruminants, has also been demonstrated (Kedderis and Rickert, 1985). 
Disposition of the sulphone metabolite is, however, dependent on it’s rate 
of formation and changes in the sulphoxide disposition induced by MTZ- 
impairment of the FMO system (Lanusse and Prichard, 1992a). The mean 
residence times and bioavailability of the inhibitors in plasma. 
Methimazole has a high bioavailability and a long half-life in plasma 
(Jansson et a/., 1985). The MRT of PB administered orally in sheep was 
38.78 hours, with an AUC value of 649.8pg.h/ml (Benchaoui, 1994). There 
is currently no published literature on the pharmacokinetics of PB in the 
horse.
In conclusion, piperonyl butoxide was found to inhibit the S-oxidation of 
fenbendazole in vitro using equine liver microsomes and this finding may 
have important applications in vivo when aiming to enhance the efficacy of 
fenbendazole.
Chapter 4 
General discussion
Feeding in the horse was demonstrated to affect the disposition kinetics of 
fenbendazole and its metabolites. Feeding principally slows the gut transit 
time which generally increases the absorption of drugs (Van Miert, 1982). 
It was difficult to make a simple assessment of the rate of absorption from 
the tmax and Cmax values alone of fenbendazole in this study. A good 
estimate of the rate of absorption is given by the absorption half-life (t1/2(a) 
= 0.693ka) and the mean absorption time (MAT =1/ka) based on the 
absorption rate constant (ka). Unfortunately this could not be determined in 
this study because it required intravenous administration. Intravenous 
administration of fenbendazole, even in dimethylsulphoxide solutions is 
not possible in the horse because of poor tolerance, at least at therapeutic 
dose rates (Q.A. McKellar, unpublished data). Absorption half-life is given 
by 0.693 X MAT , which is based on the mean absorption time (Baggot, 
1992). Absorption approximates a first-order process (i.e. the amount of 
drug administered is proportional to the amount absorbed in unit time) for 
most drugs. In comparison to unfed horses, the extent of absorption 
(bioavailability) of fenbendazole in fed horses was increased. However, 
the total bioavailability of both active compounds (fenbendazole and 
fenbendazole sulphoxide) was decreased by 50%. The sulphoxide in fed 
animals would not make much contribution to the anthelmintic effect as its 
concentrations were not only lowered but its MRT was also reduced (from 
22.94 to 7.53 hours). The duration of residence of the inactive metabolite, 
fenbendazole sulphone, was extended following feeding. The time to Cmax
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for fenbendazole was increased from 3 to 6.5 hours probably due to a 
reduced rate of absorption.
Feeding, or the time of feeding, before or after oral administration of drugs 
in the horse has also been shown to affect the pharmacokinetics of 
several other drugs. Bogan et al.} (1984) showed that the mean peak 
plasma concentration and the systemic availability of trimethoprim was 
decreased following administration of trimethoprim-sulphadiazine oral 
paste after feeding. Varying the feeding schedules in ponies together with 
administration of phenylbutazone (aqueous suspension of a granular 
formulation) produced different tmax values ( Maitho et a/., 1986); feeding 
delayed phenylbutazone absorption and yielded a non-statistically 
significant decrease in systemic availability. Post-prandial oral 
administration, as compared to pre-prandial administration of rifampin 
(5mg/kg) to horses decreased the systemic availability of the drug, but did 
not affect the rate of absorption (Baggot, 1992).
A number of studies have been carried out to improve the bioavailability 
and pharmacokinetic profiles of benzimidazole drugs and their active 
metabolites by combining them with possible potentiators. The 
bioavailability and anthelmintic efficacy of oxfendazole was improved 
when co-administered with another benzimidazole, parbendazole 
(Hennessy et al., 1985). Parbendazole is believed to potentiate the action 
of oxfendazole by inhibiting its metabolism and excretion. In humans, the
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co-administration of cimetidine with albendazole (Wen et aL, 1994) and 
mebendazole (Bekhti and Pirotte, 1987) has been shown to improve the 
clinical efficacy of the benzimidazoles against hepatic hydatid cysts by 
inhibiting metabolism, and thus the inactivation of the benzimidazoles. 
Methimazole is a flavin monooxygenase inhibitor and substrate, which has 
been shown to improve the bioavailability and disposition kinetics of 
albendazole sulphoxide after co-administration with the benzimidazole 
prodrug, netobimin, in sheep (Lanusse and Prichard, 1992a) and cattle 
(Lanusse and Prichard, 1992b). Piperonyl butoxide, an inhibitor of 
cytochrome P450, enhances the pharmacokinetic profile and anthelmintic 
efficacy of the benzimidazole, fenbendazole, in sheep and goats 
(Benchaoui and McKellar, 1996). Piperonyl butoxide is also used as a 
synergist for the ectoparasiticides, pyrethrum, pyrethroids and rotenone. 
Piperonyl butoxide was observed to improve the plasma concentration of 
fenbendazole in the horse (see Chapter 2).
The concomitant administration of fenbendazole with piperonyl butoxide in 
the horse increased the AUC of FBZ by 10 times compared to that 
observed when fenbendazole was administered alone. The plasma 
concentration of the sulphoxide metabolite was only increased when the 
horses were also fed prior to treatment with the fenbendazole-piperonyl 
butoxide combination. This metabolic inhibitor also caused the time to 
mean peak plasma concentrations to be delayed. The 
fenbendazole/fenbendazole sulphoxide ratio (based on AUCs) was
increased from 0.17 to 4.28 following administration of piperonyl butoxide 
in the unfed horses whereas it remained more or less constant in the fed 
horses. Piperonyl butoxide effect on fenbendazole metabolism in equine 
hepatic microsomes was also investigated. The extent of metabolism of 
fenbendazole was reduced leaving smaller amounts of the metabolites. 
These results, if extrapolated to anticipated in vivo results, would indicate 
that the plasma concentration of fenbendazole would be increased with 
inhibition of metabolism.
The anthelmintic efficacy of the fenbendazole-piperonyl butoxide 
combination treatment in horses with helminthiosis has yet to be 
investigated. From the studies carried out in vivo and in vitro described in 
this thesis, it is most likely that the administration of fenbendazole in 
combination with the inhibitor will result in improved anthelmintic efficacy. 
The pharmacokinetics and metabolism of fenbendazole and its 
metabolites could be markedly altered during helminthiosis in the horse, 
and this could affect the expected drug efficacy. The bioavailability of 
fenbendazole has been shown to decrease during helminth infection in 
sheep (Marriner eta!., 1985) and goats (Bogan et al., 1987). Helminthiosis 
can cause elevated gastric pH (Mostafa and McKellar et al., 1989) and 
hyperplastic changes in the abomasal mucosal mass (Anderson et al., 
1988) which could affect the absorption and ionic-trap-mediated 
distribution of fenbendazole and its metabolites. Elevated pH causes 
reduced dissolution of fenbendazole in the Gl tract and this would
contribute to reduced bioavailability. Helminth disease also affects gut 
transit times, which can influence the rate and extent of drug absorption. 
In addition, parasitism may cause altered drug metabolism and elimination 
if the liver is damaged. The interaction of helminthiosis, feed and piperonyl 
butoxide has not been investigated and even if there is some interaction it 
is not anticipated that parasitism will alter the overall conclusions reached 
in the present study with regard to food and metabolic inhibition.
The efficacy of both fenbendazole and fenbendazole sulphoxide co­
administered with piperonyl butoxide was markedly improved against the 
benzimidazole-resistant strains of Ostertagia circumcincta (Benchaoui and 
McKellar, 1996). The efficacy of FBZ prior to PB treatment was only 8%, 
which was increased to 98% following co-administration with the inhibitor. 
The benzimidazole anthelmintic, parbendazole (PBZ) was shown to 
improve the efficacy of oxfendazole in sheep experimentally infected with 
thiabendazole-resistant Haemonchus contortus and Trichostrongylus 
colubriformis (Hennessy et al., 1985). The improvement in efficacy of FBZ 
against O. circumcincta following FBZ-PB treatment was, however, 
greater than that achieved with OXF against H. contortus and 
T.colubriformis following potentiation of OXF with PBZ. Parbendazole has 
moderate anthelmintic potency but is a strong inhibitor of the 
polymerization of mammalian tubulin (Friedman and Platzer, 1978). By 
transiently binding to hepatic and kidney tubulin, PBZ reduces the rate of 
OXF biotransformation and also reduces elimination by decreasing the
biliary and urinary flow rates. This drug is also thought to increase 
anthelmintic action by increasing the extrabiliary secretion of OXF. The 
main limitation with the use of PBZ as a potentiator of OXF is the 
considerably short residence time and short time to reach mean maximum 
plasma concentrations of PBZ in relation to that of oxfendazole in sheep. 
Parbendazole improves the bioavailability, to varying degrees, of both 
FBZ and FBZSO, and thus anthelmintic efficacy of the anthelmintically 
active metabolites of FBZ and or FBZSO through altered metabolism and 
elimination. However, in contrast to PBZ, which causes metabolic 
inhibition by inhibiting microtubule assembly in mammalian hepatic or 
kidney cells, metabolic inhibition by PB is due to its interaction with the 
MFO system. This interaction results in the formation of metabolic 
intermediates which bind covalently to cytochrome P450 enzymes forming 
an inhibitory complex on enzymatic activity (Franklin, 1977). Piperonyl 
butoxide administered orally in sheep produces sustained plasma levels 
reaching a maximum concentration at 12-24 hours after administration. 
The mean residence time was about 39 hours and the drug was not 
detectable in plasma 13 days postadministration (Benchaoui, 1994). 
Piperonyl butoxide metabolic intermediates are probably more appropriate 
indicators of metabolic inhibition as they are directly involved in binding to 
and inhibiting cytochrome P450 enzymes. However, there is no published 
information on their plasma disposition in animals. Knowledge of the 
kinetic disposition of PB and its intermediates may be important in 
understanding some of the pharmacokinetic differences observed
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between small ruminants and horses when benzimidazoles are 
administered in combination with the inhibitor. The Cmax value of PB 
obtained in goats (Benchaoui, 1994) concurred with the Cmax values of 
fenbendazole and oxfendazole, which range from 6 to 30 hours (see 
Chapter one, section 1.3.5). Thus a fairly adequate interaction of PB and 
benzimidazoles would be expected in goats. In horses, the 
pharmacokinetics of PB and its intermediates may be considerably 
different due to the rapid first pass effect in this species, which may result 
in fast elimination of PB from plasma with subsequently rapid formation of 
the PB intermediates which bind to cytochrome P450. If this assumption is 
correct, it may explain, at least in part, the greater metabolic inhibition 
observed in horses (see chapter 2) compared to sheep and goats 
(Benchaoui and McKellar, 1996).
Two other compounds (cimetidine and methimazole) used in the 
potentiation of benzimidazoles also showed significant metabolic inhibition 
with improved bioavailability of the benzimidazole active moieties, and in 
the case of cimetidine anthelmintic efficacy was also improved. The 
simultaneous treatment of human patients suffering from echinococcosis 
with mebendazole and the enzyme inhibitor, cimetidine, resulted in the 
complete resolution of previously unresponsive hydatid cysts (Bekhti and 
Pirotte, 1987). Cimetidine improved the serum concentrations of MBZ by 
reducing its biotransformation rate, and this resulted in improved 
therapeutic effect. The therapeutic effect in this case was determined by
reference to the change in the extent of 14C 0 2 specific activity (SA) at 1 
hour , which was reduced from 0.89 ± 0.32 to 0.57 ± 0.17% of the 
administered dose/kg. The antithyroid compound, methimazole, has been 
shown to inhibit microsomal oxidation of different xenobiotics (Tynes and 
Hodgson, 1983), and when co-administered with the benzimidazole 
prodrug, netobimin, improved the disposition kinetics of the active moieties 
(Lanusse and Prichard, 1992a, b; Lanusse et al., 1995). However, the 
impact that these anthelmintically active metabolites with altered 
pharmacokinetics will have on parasites has yet to be determined. For the 
benzimidazole anthelmintics, effective ‘toxic’ concentrations in plasma 
must be presented to the parasite for a sufficient time to lead to 
irreversible damage ( Lanusse and Prichard, 1993b). The basic cellular 
functions of the parasite are disrupted progressively with continued 
exposure to the active drug as a result of depolymerization of 
microtubules. The parasite may survive insufficiently sustained 
concentrations of the active drug. The period of time the parasite is 
exposed to the active drug concentrations is more important than the high 
peak concentrations that are followed by fast elimination (Lanusse and 
Prichard, 1992b). The in vivo studies on the interaction of feed, FBZ and 
PB in horses reported in chapter 2 showed that the MRT of FBZ was 
extended ( from 11.68 to 17.51 hours) in unfed horses with mean 
maximum concentrations occurring at 17 hours. In the fed horses the MRT 
of FBZ was only extended by about one hour with tmax value at 13.6 hours. 
The co-administration of FBZ with the inhibitor slightly decreased the MRT
of the sulphoxide metabolite in unfed horses, but this was approximately 
doubled ( from 7.53 to 13.56 hours) in the fed horses. The tmax values of 
the active metabolites/drugs occurred at about the same times in the fed 
horses, as was also the case in the unfed horses even though they 
occurred at an earlier time than in the unfed horses. In unfed horses, it 
was observed that the tmax value of FBZSO occurred at a considerably 
longer time (at 22.67 hours) than the tmax values of FBZSO (fed horses) 
and FBZ (fed or unfed horses), which ranged from 3 to 6.5 hours after co­
administration of fenbendazole and PB. The reason why the MRT of 
FBZSO in unfed horses was not extended with concomitant administration 
of PB could be due to the disposition kinetics of PB and/ or intermediates 
in the plasma. It may be that PB is rapidly excreted and diminishing 
amounts with time in the plasma are insufficient to maintain metabolic 
inhibition of sulphonation. The MRT of FBZSO, even though not reduced 
with PB adiministration, is relatively high at 22.67 hours, and PB may have 
a much shorter MRT in the horse. Furthermore, PB is known to cause 
metabolic induction from 24-72 hours after administration (Skrinjaric- 
Spoljar et a/., 1971), and this may explain why the FBZSO MRT is not 
further extended.
The prolongation of the residence times of the metabolites in plasma by 
metabolic inhibition with PB may also increase the level of the anthelmintic 
residues in various tissues of the animal, which may jeopardise regulatory 
requirements. Obtaining approval from regulatory authorities for drug
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combinations is difficult. Further research is required to determine the 
change in the amounts of anthelmintic residues in animal tissues caused 
by use of PB as a metabolic inhibitor. This is particularly important in 
animals that are used for food for human consumption. Piperonyl butoxide 
may also be widely distributed in animal tissues, and there is need to 
investigate its level of toxicity in ruminants and horses.
Considering the tremendous level of metabolic inhibition of FBZ when co­
administered with PB after feeding, and the consequent considerable 
improvement in the disposition of the anthelmintically active drugs, this 
drug combination is most likely to be practical in anthelmintic 
chemotherapy. Furthermore, PB is a relatively inexpensive compound and 
its simultaneous use with benzimidazoles will be of economic benefit in 
terms of endoparasite control. A better assessment of the practicality of 
the combination would be better made after further research, e.g. 
anthelmintic efficacy studies and appropriate FBZ-PB dosage regimens 
that produce optimum efficacy at a lower cost.
In conclusion, fenbendazole should be administered without food in the 
horse, as this will cause increased bioavailability of active moieties and 
improve expected anthelmintic efficacy. The effect of piperonyl butoxide, 
whether administered with or without food, on fenbendazole disposition 
and kinetics was to increase its bioavailability.
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Appendix A
A-1 Recovery and coefficients of variation for fenbendazole metabolites 
following liquid phase extraction from plasma.
Added
Concentration
(pg/ml)
Recovery
(%)
Between-assay 
coefficient of 
variation (%)
FBZ 0.05 88.59 (n=6) 10.22
0.10 82.02 (n=6) 13.24
0.25 83.35 (n=6) 16.79
0.50 81.14 (n=6) 11.73
1.00 83.33 (n=6) 13.42
Mean 83.68 (n=30) 13.08
FBZSO 0.05 93.60 (n=6) 14.96
0.10 86.57 (n=6) 10.64
0.25 92.85 (n=6) 10.50
0.50 89.84 (n=6) 10.48
1.00 90.55 (n=6) 10.72
Mean 90.68 (n=30) 11.46
f b z s o 2 0.05 96.10 (n=6) 10.74
0.10 92.26 (n=6) 10.94
0.25 96.97 (n=6) 13.00
0.50 90.50 (n=6) 8.72
1.00 90.26 (n=6) 8.97
Mean 93.22 (n=30) 10.47
Coefficient of variation = ( SD/ mean recovery) X 100
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A-2 Plasma concentrations of fenbendazole (FBZ)(pg/ml) following
adminstration of fenbendazole (10mg/kg) alone with food in horses.
Animal number
Time(h) 1 2 3 4 5 6
0 0.000 0.000 0.000 0.000 0.000 0.000
1 0.016 0.029 0.024 0.000 0.030 0.019
2 0.017 0.037 0.037 0.004 0.033 0.036
3 0.013 0.016 0.023 0.004 0.078 0.021
4 0.000 0.056 0.038 0.008 0.032 0.019
6 0.000 0.016 0.028 0.013 0.041 0.023
8 ND 0.016 0.043 0.006 0.029 0.023
12 0.000 0.013 0.044 0.005 0.019 0.024
24 0.032 0.012 0.031 0.000 0.009 0.011
32 0.000 0.000 0.000 0.000 0.000 0.000
48 0.027 0.000 0.000 0.000 0.000 0.000
72 0.000 0.000 0.000 0.003 0.000 0.000
96 0.000 0.000 0.000 0.003 0.000 0.000
A-3 Pharmacokinetic parameters of fenbendazole (FBZ)(jig/ml) following 
adminstration of fenbendazole (10mg/kg) alone with food in horses.
Animal number
1 2 3 4 5 6
AUCobs.(|jg.h/ml) 0.23 0.42 0.82 0.15 0.58 0.43
AUMCobs (pg.h/ml) 4.41 3.65 9.88 1.38 5.07 4.36
MRT (h) 19.17 8.69 12.05 9.52 8.82 10.14
Cmax (M9/ml) 0.03 0.06 0.04 0.01 0.08 0.04
tmax (h) 24 4 2 4 3 2
I l l
A-4 Plasma concentrations of fenbendazole (FBZ)(pg/ml) following
adminstration of fenbendazole (10mg/kg) alone without food in horses.
Animal number
Time(h) 1 2 3 4 5 6
0 0.000 0.000 0.010 0.000 0.000 0.000
1 0.023 0.000 0.036 0.009 0.000 0.000
2 0.027 0.000 0.039 0.010 0.017 0.000
3 0.031 0.000 0.040 0.000 0.014 0.000
4 0.018 0.000 0.041 0.008 0.000 0.000
6 0.024 0.000 0.029 0.006 0.011 0.000
8 0.023 0.000 0.029 0.009 0.000 0.000
12 0.000 0.000 0.019 0.013 0.000 0.022
24 0.018 0.000 0.010 0.012 0.000 0.017
32 0.000 0.000 0.008 0.008 0.000 0.000
48 0.000 0.000 0.000 0.000 0.000 0.000
72 0.000 0.000 0.000 0.000 0.000 0.000
96 0.000 0.000 0.009 0.000 0.000 0.029
A-5 Pharmacokinetic parameters of fenbendazole (FBZ)(pg/ml) following 
adminstration of fenbendazole (10mg/kg) alone without food in horses.
Animal number
1 2 3 4 5 6
AUCobs. (pg.h/ml) 0.41 0.00 0.72 0.39 0.05 0.36
AUMCobs.(pg.h/ml) 5.81 0.00 9.72 7.65 0.19 6.72
MRT (h) 14.17 0.00 13.59 19.87 3.80 18.67
Cmax (Mg/ml) 0.03 0.00 0.04 0.01 0.02 0.02
m^ax (t"0 2.00 0.00 1.00 1.00 2.00 12.00
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A-6 Plasma concentrations of fenbendazole (FBZ)(pg/ml) following
adminstration of fenbendazole (10mg/kg) in combination with piperonyl
butoxide (PB) (63mg/kg) with food in horses.
Animal number
Time(h) 1 3 4 5 6
0 0.000 0.005 0.000 0.000 0.000
1 0.029 0.043 0.050 0.155 0.139
2 0.036 0.065 0.078 0.191 0.218
3 0.048 0.066 0.089 0.275 0.207
4 0.053 0.327 0.161 0.508 0.250
6 0.049 0.059 0.165 0.372 0.256
8 0.069 0.052 0.159 0.656 0.553
12 0.076 0.018 0.196 0.649 0.451
24 0.088 0.005 0.231 0.137 0.323
32 0.018 0.000 0.008 0.000 0.000
48 0.000 0.000 0.049 0.000 0.128
72 0.000 0.000 0.000 0.000 0.000
96 0.000 0.000 0.000 0.000 0.000
A-7 Pharmacokinetic parameters of fenbendazole (FBZ)(jng/ml) following 
adminstration of fenbendazole (10mg/kg) in combination with piperonyl 
butoxide (PB) (63mg/kg) with food in horses.
Animal number
1 3 4 5 6
AUCobs. (pg.h/ml) 2.125 1.105 5.22 10.71 9.915
AUMCobs.(pg.h/ml) 34.68 6.21 83 120.7 139
MRT (h) 16.32 5.62 15.9 11.27 14.02
Cmax (Mg/ml) 0.09 0.33 0.23 0.66 0.55
m^ax (h) 24 4 24 8 8
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A-8 Plasma concentrations of fenbendazole (FBZ)(pg/ml) following
adminstration of fenbendazole (10mg/kg) in combination with piperonyl
butoxide (PB) (63mg/kg) without food in horses.
Animal number
Time(h) 1 2 3 4 5 6
0 0.00 0.00 0.00 0.00 0.00 0.01
1 0.01 0.00 0.02 0.03 0.04 0.06
2 0.01 0.00 0.04 0.09 0.10 0.08
3 0.02 0.00 0.04 0.14 0.13 0.08
4 0.02 0.02 0.04 0.13 0.13 0.07
6 0.02 0.03 0.05 0.16 0.17 0.07
8 0.05 0.04 0.08 0.15 0.14 0.07
12 0.13 0.10 0.14 0.21 0.14 0.10
24 0.20 0.12 0.12 0.19 0.04 0.13
32 0.04 0.03 0.06 0.04 0.00 0.03
48 0.00 0.00 0.00 0.00 0.00 0.00
72 0.00 0.00 0.00 0.00 0.00 0.00
96 0.00 0.00 0.00 0.00 0.00 0.00
A-9 Pharmacokinetic parameters of fenbendazole (FBZ)(pg/ml) following 
adminstration of fenbendazole (10mg/kg) in combination with piperonyl 
butoxide (PB) (63mg/kg) without food in horses.
Animal number
1 2 3 4 5 6
AUCobs. (pg.h/ml) 3.78 2.57 3.54 5.28 2.74 3.14
AUMCobs.(pg.h/ml) 77.49 51.36 68.26 88.05 29.85 55.72
MRT (h) 20.50 19.98 19.28 16.66 10.87 17.74
Cmax (Mg/ml) 0.20 0.12 0.14 0.21 0.17 0.13
tmax (h) 24.00 24.00 12.00 12.00 6.00 24.00
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A-10 Plasma concentrations of fenbendazole suphoxide (FBZSO)(^ig/ml)
following adminstration of fenbendazole (10mg/kg) alone with food in
horses.
Animal number
Time(h) 1 2 3 4 5 6
0 0.000 0.000 0.000 0.000 0.008 0.000
1 0.003 0.004 0.000 0.000 0.009 0.000
2 0.004 0.006 0.011 0.004 0.010 0.005
3 0.003 0.006 0.006 0.004 0.020 0.004
4 0.016 0.015 0.010 0.008 0.011 0.002
6 0.004 0.005 0.002 0.013 0.024 0.000
8 ND 0.008 0.008 0.006 0.025 0.004
12 0.005 0.005 0.006 0.005 0.030 0.002
24 0.004 0.000 0.000 0.000 0.000 0.000
32 0.002 0.000 0.000 0.000 0.012 0.000
48 0.005 0.000 0.000 0.000 0.000 0.003
72 0.000 0.000 0.000 0.003 0.000 0.000
96 0.016 0.000 0.000 0.003 0.000 0.000
A-11 Pharmacokinetic parameters of fenbendazole suphoxide (FBZSO) 
(ng/ml) following adminstration of fenbendazole (10mg/kg) alone with food 
in horses.
Animal number
1 2 3 4 5 6
AUCobs. (pg.h/ml) 0.11 0.09 0.15 0.15 0.43 0.01
AUMCobs.(pg.h/ml) 1.08 0.47 1.31 1.38 3.99 0.02
MRT (h) 9.82 5.53 9.03 9.52 9.28 2.00
Cmax (Mg/ml) 0.02 0.01 0.01 0.01 0.03 0.01
tmax (^) 4 2 2 4 8 2
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A-12 Plasma concentrations of fenbendazole sulphoxide (FBZSO)(^g/ml)
following adminstration of fenbendazole (10mg/kg) alone without food in
horses.
Animal number
Time(h) 1 2 3 4 5 6
0 0.00 0.00 0.00 0.00 0.00 0.00
1 0.00 0.00 0.00 0.00 0.00 0.00
2 0.00 0.00 0.00 0.00 0.00 0.00
3 0.00 0.00 0.04 0.00 0.02 0.00
4 0.00 0.00 0.04 0.00 0.02 0.00
6 0.00 0.00 0.04 0.00 0.02 0.00
8 0.00 0.01 0.04 0.00 0.03 0.00
12 0.06 0.04 0.04 0.00 0.03 0.00
24 0.05 0.05 0.05 0.00 0.05 0.00
32 0.07 0.05 0.04 0.00 0.06 0.00
48 0.06 0.06 0.04 0.00 0.05 0.00
72 0.00 0.00 0.00 0.00 0.02 0.00
96 0.00 0.00 0.00 0.00 0.00 0.00
A-13 Pharmacokinetic parameters of fenbendazole sulphoxide (FBZSO) 
(ng/ml) following adminstration of fenbendazole (10mg/kg) alone without 
food in horses.
Animal number
1 2 3 4 5 6
AUCobs. (pg.h/ml) 3.02 2.65 2.40 0.00 3.12 0.00
AUMCobs.(pg.h/ml) 102.24 92.88 71.40 0.00 121.62 0.00
MRT (h) 33.85 35.05 29.75 0.00 38.98 0.00
Cmax (MQ/ml) 0.07 0.06 0.05 0.00 0.06 0.00
tmax (h) 32 48 24 0 32 0
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A-14 Plasma concentrations of fenbendazole sulphoxide (FBZSO)(|ig/ml)
following adminstration of fenbendazole (10mg/kg) in combination with
piperonyl butoxide (PB) (63mg/kg) with food in horses.
Animal number
Time(h) 1 3 4 5 6
0 0.000 0.003 0.000 0.000 0.000
1 0.000 0.004 0.009 0.046 0.009
2 0.000 0.006 0.015 0.071 0.016
3 0.005 0.008 0.019 0.105 0.015
4 0.005 0.046 0.040 0.205 0.026
6 0.007 0.011 0.050 0.153 0.040
8 0.010 0.011 0.073 0.307 0.075
12 0.009 0.004 0.111 0.393 0.070
24 0.017 0.004 0.141 0.070 0.068
32 0.002 0.000 0.002 0.000 0.000
48 0.000 0.000 0.026 0.000 0.022
72 0.000 0.000 0.000 0.000 0.000
96 0.000 0.000 0.000 0.000 0.000
A-15 Pharmacokinetic parameters of fenbendazole sulphoxide (FBZSO) 
(ng/ml) following adminstration of fenbendazole (10mg/kg) in combination 
with piperonyl butoxide (PB) (63mg/kg) with food in horses.
Animal number
1 3 4 5 6
AUCobs. (pg.h/ml) 0.34 0.15 2.69 5.60 1.65
AUMCobs.(pg.h/ml) 6.15 0.71 46.77 65.26 25.97
MRT (h) 18.09 4.90 17.39 11.66 15.79
Cmax (Mg/ml) 0.02 0.05 0.14 0.39 0.07
m^ax (h) 24 4 24 12 8
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A-16 Plasma concentrations of fenbendazole sulphoxide (FBZSO)(pg/ml)
following adminstration of fenbendazole (10mg/kg) in combination with
piperonyl butoxide (PB) (63mg/kg) without food in horses.
Animal number
Time(h) 1 2 3 4 5 6
0 0.000 0.000 0.000 0.000 0.000 0.000
1 0.000 0.000 0.000 0.000 0.000 0.000
2 0.000 0.000 0.000 0.000 0.000 0.000
3 0.000 0.000 0.000 0.012 0.011 0.000
4 0.000 0.000 0.000 0.011 0.016 0.010
6 0.000 0.000 0.000 0.020 0.031 0.010
8 0.000 0.000 0.000 0.022 0.033 0.037
12 0.009 0.013 0.018 0.044 0.027 0.050
24 0.046 0.037 0.029 0.047 0.000 0.020
32 0.000 0.000 0.000 0.013 0.000 0.047
48 0.000 0.000 0.000 0.019 0.000 0.008
72 0.000 0.000 0.000 0.000 0.000 0.000
96 0.000 0.000 0.000 0.000 0.000 0.000
A-17 Pharmacokinetic parameters of fenbendazole sulphoxide (FBZSO) 
(pg/ml) following adminstration of fenbendazole (10mg/kg) in combination 
with piperonyl butoxide (PB) (63mg/kg) without food in horses.
Animal number
1 2 3 4 5 6
AUCobs. 0.53 0.48 0.46 1.46 0.43 1.55
(pg.h/ml)
AUMCobs. 11.90 10.56 9.12 39.69 4.11 39.54
(pg.h/ml) 
MRT (h) 22.38 22.00 19.83 27.09 9.56 25.43
Cmax (pg/ml) 0.05 0.04 0.03 0.05 0.03 0.05
m^ax (h) 24 24 24 24 6 12
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A-18 Plasma concentrations of fenbendazole suphone (FB ZS02)(pg/ml)
following adminstration of fenbendazole (10mg/kg) alone with food in
horses.
Animal number
Time(h) 1 2 3 4 5 6
0 0.000 0.000 0.000 0.005 0.015 0.006
1 0.013 0.029 0.009 0.012 0.039 0.037
2 0.037 0.065 0.036 0.021 0.054 0.014
3 0.037 0.063 0.028 0.027 0.077 0.019
4 0.067 0.138 0.054 0.038 0.066 0.009
6 0.018 0.056 0.045 0.059 0.119 0.015
8 ND 0.038 0.079 0.057 0.095 0.019
12 0.038 0.048 0.054 0.033 0.087 0.024
24 0.033 0.019 0.030 0.017 0.036 0.029
32 0.009 0.007 0.008 0.021 0.021 0.029
48 0.061 0.012 0.015 0.013 0.017 0.004
72 0.006 0.000 0.000 0.008 0.004 0.006
96 0.009 0.010 0.000 0.003 0.025 0.006
A-19 Pharmacokinetic parameters of fenbendazole suphone (FB ZS02) 
(pg/ml) following adminstration of fenbendazole (10mg/kg) alone with food 
in horses.
Animal number
1 2 3 4 5 6
AUCobs. (pg.h/ml) 1.55 1.41 1.40 1.18 2.32 0.99
AUMCobs.(pg.h/ml) 39.51 20.15 22.68 21.74 38.00 21.42
MRT (h) 25.57 14.29 16.26 18.42 16.41 21.64
Cmax (MQ/ml) 0.07 0.14 0.08 0.06 0.12 0.04
tmax (^0 4 4 8 6 6 1
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A-20 Plasma concentrations of fenbendazole (FBZS02)(pg/ml) following
adminstration of fenbendazole (10mg/kg) alone without food in horses.
Animal number
Time(h) 1 2 3 4 5 6
0 0.00 0.00 0.00 0.00 0.00 0.00
1 0.01 0.01 0.00 0.00 0.00 0.00
2 0.03 0.02 0.07 0.00 0.01 0.00
3 0.04 0.02 0.10 0.00 0.02 0.00
4 0.03 0.02 0.11 0.00 0.02 0.00
6 0.03 0.01 0.11 0.01 0.03 0.00
8 0.04 0.01 0.10 0.02 0.02 0.00
12 0.02 0.02 0.05 0.00 0.04 0.00
24 0.02 0.01 0.02 0.03 0.04 0.00
32 0.01 0.00 0.02 0.03 0.03 0.00
48 0.00 0.00 0.03 0.01 0.02 0.01
72 0.00 0.00 0.03 0.01 0.00 0.00
96 0.00 0.00 0.02 0.00 0.00 0.00
A-21 Pharmacokinetic parameters of fenbendazole (FB ZS02)(pg/ml) 
following adminstration of fenbendazole (10mg/kg) alone without food in 
horses.
Animal number
1 2 3 4 5 6
AUCobs. (pg.h/ml) 0.79 0.39 3.50 1.18 1.66 0.20
AUMCobs.(pg.h/ml) 12.25 4.91 148.82 46.20 45.20 9.60
MRT (h) 15.61 12.59 42.58 39.15 27.23 48.00
Cmax (M9/ml) 0.00 0.02 0.11 0.03 0.04 0.01
tmax (h) 3 2 4 24 12 48
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A-22 Plasma concentrations of fenbendazole (FB ZS02)(ng/ml) following
adminstration of fenbendazole (10mg/kg) in combination with piperonyl
butoxide (PB) (63mg/kg) with food in horses.
Animal number
Time(h) 1 3 4 5 6
0 0.000 0.012 0.000 0.000 0.000
1 0.000 0.010 0.000 0.000 0.000
2 0.000 0.007 0.000 0.009 0.000
3 0.000 0.006 0.000 0.009 0.000
4 0.000 0.017 0.000 0.015 0.000
6 0.012 0.015 0.000 0.008 0.009
8 0.013 0.015 0.007 0.025 0.018
12 0.023 0.057 0.017 0.041 0.027
24 0.139 0.014 0.079 0.213 0.066
32 0.037 0.009 0.016 0.000 0.013
48 0.000 0.008 0.137 0.045 0.166
72 0.006 0.004 0.000 0.000 0.000
96 0.005 0.007 0.000 0.000 0.000
A-23 Pharmacokinetic parameters of fenbendazole (FB ZS02)(pg/ml) 
following adminstration of fenbendazole (10mg/kg) in combination with 
piperonyl butoxide (PB) (63mg/kg) with food in horses.
Animal number
1 3 4 5 6
AUCobs.(pg.h/ml) 1.77 0.74 1.07 2.57 1.06
AUMCobs.(pg.h/ml) 41.00 9.98 23.92 55.19 21.56
MRT (h) 23.16 13.58 22.36 21.52 20.34
c max (Mg/ml) 0.14 0.06 0.08 0.21 0.07
XreE 24 12 24 24 24
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A-24 Plasma concentrations of fenbendazole (FBZS02)(pg/ml) following
adminstration of fenbendazole (10mg/kg) in combination with piperonyl
butoxide (PB) (63mg/kg) without food in horses.
Animal number
Time(h) 1 2 3 4 5 6
0 0.00 0.00 0.00 0.00 0.00 0.00
1 0.00 0.00 0.00 0.00 0.00 0.00
2 0.00 0.00 0.00 0.00 0.01 0.00
3 0.00 0.00 0.00 0.00 0.00 0.00
4 0.00 0.00 0.00 0.00 0.02 0.00
6 0.00 0.00 0.00 0.00 0.00 0.00
8 0.00 0.00 0.03 0.00 0.02 0.00
12 0.00 0.05 0.00 0.01 0.02 0.00
24 0.00 0.08 0.02 0.05 0.06 0.06
32 0.00 0.00 0.03 0.07 0.02 0.08
48 0.00 0.00 0.02 0.00 0.01 0.00
72 0.00 0.00 0.03 0.00 0.01 0.00
96 0.00 0.00 0.00 0.00 0.01 0.00
A-25 Pharmacokinetic parameters of fenbendazole (FB ZS02)(pg/ml) 
following adminstration of fenbendazole (10mg/kg) in combination with 
piperonyl butoxide (PB) (63mg/kg) without food in horses.
Animal number
1 2 3 4 5 6
AUCobs. (pg.h/ml) 0.00 1.20 1.77 1.42 1.78 1.56
AUMCobs.(pg.h/ml) 0.00 24.00 88.08 39.84 74.54 45.12
MRT (h) 0.00 20.00 49.76 28.06 41.88 28.92
Cmax (MQ/ml) 0.00 0.08 0.03 0.07 0.06 0.08
tmax (h) 0 24 8 32 24 32
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Appendix B
Appendix B-1. Quantities of components of the NADPH-generating 
cofactor solution sufficient for ten assays.
Component Amount required per ten assays
Tris buffer, pH 7.4 , 0.1M 8.5 ml
MgCI2 , 0.15M 1.0 ml
Nicotinamide, 0.5M 1.0 ml
Trisodium isocitrate 40 mg
Isocitrate dehydrogenase 2 units
NADP+ 8 mg
N.B. (a) 1.0 ml of the above solution is usually required per assay.
(b) The components should be thoroughly mixed and dissolved 
prior to use.
(c) The mixed solution should not be allowed to stand for more than 
a few minutes, otherwise the generated NADPH will break 
down.
Appendix B-2. Calculated amounts of microsomal protein/suspension used.
A B C D E F
Microsomal protein 
(mg/g of liver) 5.56 2.30 1.52 6.05 3.51 5.98
Microsomal protein
(mg/ml of microsome suspension) 8.82 2.55 3.38 11.20 5.48 9.06
Weight of liver used (g)
100 71.43 100 100 100 100
Final volume of microsome 
suspension (ml) 63 64.5 45 54 64 66
Volume of microsome suspension 
(ml) per 4 mg protein 0.454 1.567 1.185 0.357 0.730 0.442
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Appendix B-3. Microsomal protein used in incubation of microsomes with 
oxfendazole in equine liver (n=4).
A B C D Mean ± SEM
Microsomal protein 
( mg/g of liver) 5.56 2.30 1.52 6.05 3.86 ±1 .14
Appendix B-4. Microsomal protein used in incubation of microsomes with 
fenbendazole in equine liver (n=4).
A D E F Mean ± SEM
Microsomal protein 
( mg/g of liver) 5.56 6.05 3.51 5.98 5.28 ± 0.60
Appendix B-5. Amount of drug and metabolites recovered (nmoles/ml) 
after incubation without microsomes.
Sulphide Sulphoxide Sulphone
OXF (n=3) 0.00 18.36 0.26
FBZ (n=3) 55.06 0.00 0.00
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Appendix B-6. Amount of oxfendazole (OXF) (nmoles/ml) remaining in the
microsomal reaction mixture after incubation with OXF.
OXF (nmoles/ml)
Cone.
0*M)
A B C D Mean ± SEM
With PB 5
(n=3) 5.81 6.78 - 16.74 9.78 ± 3.47
10
(n=3) 15.10 15.54 - 38.06 22.90 ± 6.56
25
(n=4) 42.83 42.53 27.30 125.89 59.64 ± 23.53
50
(1=4) 64.85 64.38 59.87 189.34 94.61 ± 34.59
Without
PB
5
(n=4) 6.52 6.75 9.46 17.84 10.14 ±3 .2 3
10
(n=3) 13.73 13.2 - 26.80 17.91 ± 4 .4 5
25
(n=3) 31.97 32.21 - 77.35 47.18 ±27 .24
50 - - - - -
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Appendix B-7. Amount of fenbendazole (FBZ) (nmoles/ml) remaining in
the microsomal reaction mixture after incubation with FBZ.
FBZ (nmoles/ml) (n=4)
Cone.
GiM)
A D E F Mean ± SEM
With PB
5 5.38 5.51 9.22 5.18 6.32 ±1 .64
10 8.39 8.62 20.11 7.89 11.25 ± 3 .59
25 25.33 26.16 50.02 23.66 31.29 ±8 .85
50 38.39 39.79 58.64 42.00 44.70 ± 10.79
Without
PB 5 7.22 0.67 6.01 3.91 4.45 ± 1.59
10 9.02 1.34 8.69 8.69 6.93 ± 2.24
25
(n=3) 44.24 2.64 - 25.46 24.11 ± 12.03
50 35.52 3.51 72.10 37.45 37.15 ± 14.71
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Appendix B-8. Amount of fenbendazole sulphone (0 X F S 0 2) (nmoles/mg
protein/hour) formed in microsomal reaction mixture after incubation of
oxfendazole with or without piperonyl butoxide (PB) in equine liver.
0 X F S 0 2 formed 
(nmoles/mg protein/hour) (n=4)
Cone.
(pM)
A B C D Mean ± SEM
With PB 5
(n=3) 0.02 0.03 - 0.03 0.03 ±0.01
10
(n=3) 0.10 0.05 - 0.06 0.07 ± 0.02
25 0.13 0.18 0.22 0.21 0.18 ± 0 .04
50 0.14 0.29 0.29 0.30 0.26 ± 0.07
Without
PB 5 0.18 0.04 0.18 0.05 0.11 ±0 .04
10 0.19 0.07 6.65 0.07 1.75 ±1 .47
25 0.15 0.20 10.47 0.20 2.76 ±2.31
50 0.08 0.01 16.43 0.35 4.22 ± 3.65
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Appendix B-9. Amount of fenbendazole (FBZ) (nmoles/mg protein/hour)
formed in microsomal reaction mixture after incubation of oxfendazole with
or without piperonyl butoxide (PB) in equine liver.
FBZ formed 
(nmoles/mg protein/hour) (n=4)
Cone.
(pM)
A B C D Mean ± SEM
With PB 5
(n=3) 0.02 0.05 - 0.11 0.06 ± 0.03
10
(n=3) 0.02 0.07 - 0.16 0.08 ± 0.04
25 0.06 0.16 0.65 0.08 0.24 ±0 .13
50 0.09 0.15 0.59 0.32 0.29 ±0 .12
Without
PB 5 0.71 0.12 1.04 0.12 0.50 ± 0.23
10 1.49 0.22 20.41 0.24 5.59 ±4 .46
25 3.47 0.38 42.98 0.48 11.83 ±9 .39
50 0.01 0.00 74.60 0.64 18.81 ± 16.65
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Appendix B-10. Amount of fenbendazole sulphoxide (FBZSO) (nmoles/mg
protein/hour) formed in microsomal reaction mixture after incubation of
fenbendazole with or without piperonyl butoxide (PB) in equine liver.
FBZSO formed 
(nmoles/mg protein/hour) (n=4)
Cone.
(pM)
A D E F Mean ± SEM
With PB
5 0.03 0.03 0.07 0.03 0.04 ±0.01
10 0.04 0.04 0.16 0.06 0.07 ± 0.03
25 0.08 0.07 0.15 0.11 0.10 ± 0 .0 3
50 0.09 0.09 0.15 0.09 0.10 ±0 .03
Without
PB 5 0.08 2.22 0.14 0.03 0.62 ± 0.48
10 0.11 3.34 0.16 0.05 0.91 ± 0 .7 3
25 0.17 9.63 0.28 0.13 2.55 ±2 .1 2
50 0.50 20.19 0.35 0.16 5.21 ± 4 .4 8
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Appendix B-11. Amount of fenbendazole sulphone (FB ZS02) (nmoles/mg
protein/hour) formed in microsomal reaction mixture after incubation of
fenbendazole with or without piperonyl butoxide (PB) in equine liver.
FBZS02 formed 
(nmoles/mg protein/hour) (n=4)
Cone.
(pM)
A D E F Mean ± SEM
With PB
5 0.04 0.03 0.03 0.06 0.04 ±0.01
10 0.04 0.08 0.10 0.06 0.07 ±0.01
25 0.04 0.05 0.06 0.08 0.06 ±0.01
50 0.05 0.06 0.10 0.08 0.07 ± 0.02
Without
PB 5 0.04 0.06 0.02 0.00 0.03 ±0.01
10 0.11 0.09 0.00 0.04 0.06 ± 0.03
25 0.11 0.25 0.07 0.05 0.12 ± 0 .0 5
50 0.13 0.43 0.07 0.06 0.17 ±0 .08
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